Your browser is no longer supported. Please, upgrade your browser.
Settings
FB Facebook, Inc. daily Stock Chart
FB [NASD]
Facebook, Inc.
IndexS&P 500 P/E21.68 EPS (ttm)7.58 Insider Own1.28% Shs Outstand2.93B Perf Week-0.99%
Market Cap480.87B Forward P/E18.52 EPS next Y8.87 Insider Trans-2.34% Shs Float2.35B Perf Month2.69%
Income22.11B PEG1.32 EPS next Q1.63 Inst Own74.70% Short Float0.91% Perf Quarter23.34%
Sales55.84B P/S8.61 EPS this Y22.90% Inst Trans1.94% Short Ratio1.00 Perf Half Y0.78%
Book/sh29.26 P/B5.62 EPS next Y17.48% ROA24.00% Target Price196.46 Perf Year-2.98%
Cash/sh14.05 P/C11.70 EPS next 5Y16.43% ROE27.50% 52W Range123.02 - 218.62 Perf YTD25.36%
Dividend- P/FCF31.31 EPS past 5Y66.30% ROI25.80% 52W High-24.83% Beta0.89
Dividend %- Quick Ratio7.20 Sales past 5Y48.00% Gross Margin83.20% 52W Low33.59% ATR3.85
Employees35587 Current Ratio7.20 Sales Q/Q30.40% Oper. Margin44.60% RSI (14)51.42 Volatility2.29% 1.97%
OptionableYes Debt/Eq0.00 EPS Q/Q7.80% Profit Margin39.60% Rel Volume0.77 Prev Close166.08
ShortableYes LT Debt/Eq0.00 EarningsJan 30 AMC Payout0.00% Avg Volume21.32M Price164.34
Recom2.00 SMA20-1.42% SMA502.47% SMA200-0.25% Volume16,364,325 Change-1.05%
Mar-18-19Downgrade Needham Buy → Hold
Mar-11-19Upgrade Nomura Neutral → Buy $172 → $215
Jan-31-19Reiterated UBS Neutral $160 → $170
Jan-31-19Reiterated Rosenblatt Buy $206 → $212
Jan-31-19Reiterated RBC Capital Mkts Outperform $190 → $200
Jan-31-19Reiterated Raymond James Outperform $180 → $200
Jan-31-19Reiterated Pivotal Research Group Sell $113 → $120
Jan-31-19Reiterated Oppenheimer Outperform $185 → $195
Jan-31-19Reiterated Nomura Neutral $148 → $172
Jan-31-19Reiterated Morgan Stanley Overweight $175 → $190
Jan-31-19Reiterated Mizuho Buy $200 → $210
Jan-31-19Reiterated Macquarie Outperform $190 → $195
Jan-31-19Reiterated JMP Securities Mkt Outperform $176 → $195
Jan-31-19Reiterated Jefferies Buy $180 → $200
Jan-31-19Reiterated Credit Suisse Outperform $208 → $210
Jan-31-19Reiterated Citigroup Buy $175 → $185
Jan-31-19Reiterated Canaccord Genuity Buy $180 → $200
Jan-31-19Reiterated BofA/Merrill Buy $190 → $205
Dec-21-18Reiterated Needham Buy $215 → $170
Dec-06-18Initiated Guggenheim Neutral $150
Mar-22-19 06:33PM  A Beginner's Guide to Buying Facebook Stock Investopedia
05:44PM  Amid Bay Area exodus, some companies rush into region American City Business Journals
05:20PM  Pinterest's IPO filing shows how dependent websites and apps have become on Google and Facebook CNBC
05:05PM  Here's what happened when Frank Gehry met Mark Zuckerberg to discuss Building X American City Business Journals
04:36PM  3 Blue-Chip Stocks to Buy Right Now Zacks
04:24PM  Pinterest files to go public: Booked $756 million last year and claims 250 million monthly users CNBC
03:29PM  The Biggest Threats Facing Tech Stocks Now Investopedia
03:24PM  Unicorns: The Next Generation of $1 Billion Startups Has Arrived Investopedia
02:10PM  Earnings Reports for the Week of March 25-29 (CRON, LULU, OLLI) Kiplinger
02:01PM  Why You Need to Change Your Facebook Password Now! InvestorPlace
01:31PM  How To Buy IPO Stocks: Lessons From Facebook, Alibaba, Snap, Square And Tencent Music Investor's Business Daily
01:28PM  Challenges for Facebook a year after Cambridge Analytica scandal CBS News Videos
12:35PM  Facebook admits millions of user passwords were visible to employees Fox Business Videos
11:40AM  Women are still underrepresented in tech. Heres what Facebook has to say about it. Mashable Videos
11:03AM  Here's What to Expect (and Hope For) From the Oculus Quest Motley Fool
10:32AM  Can Amazon's Video Ad Plans Disrupt Google-Facebook Duopoly? Zacks
10:21AM  Mobile Ad Push Could Boost Amazon Stock InvestorPlace
09:47AM  You may be earning less than a 20-year-old Silicon Valley intern CNBC
08:55AM  Snap to drug advertisers: We're the friendlier social network CNBC
08:30AM  How to Fix Big Tech Without Breaking It Up Bloomberg
08:00AM  Some Tech Workers Are Open To Breaking Up Facebook, Google, and Amazon, Poll Finds Barrons.com
07:19AM  German minister on Facebook password glitch: Didn't expect such frightening unprofessionalism Reuters
07:00AM  Facebook crumbles around its lonely king MarketWatch
06:00AM  Facebook Stopped Bangladeshi Ad Farm Targeting Utah in Midterms Bloomberg
05:31AM  Facebook fixes glitch that exposed millions of user passwords to employees Reuters
01:58AM  Facebook, Instagram, Twitter: What's your relationship with them like? CNET
Mar-21-19 10:13PM  Facebook blunders password management, AT&T and Comcast take on robocalls CNET
07:49PM  Facebook left millions of passwords readable by employees Associated Press
05:45PM  Facebook (FB) Gains But Lags Market: What You Should Know Zacks
05:22PM  Business Highlights Associated Press
04:51PM  Facebook stored some passwords in plain text CBS News Videos
04:17PM  Is Facebook Past Its Prime As The Stock Market Grinds Higher? Investor's Business Daily
03:34PM  Why Lululemon (LULU) Stock Looks Like a Buy Heading into Q4 Earnings Zacks
03:06PM  The Afternoon Rundown: March 21, 2019 CNBC Videos
02:54PM  Millions of Facebook, Instagram passwords exposed internally, company says MarketWatch
02:50PM  The 7 Best Stocks in the Entrepreneur Index InvestorPlace
02:40PM  Facebook left millions of passwords readable by employees Associated Press
01:53PM  Facebook Doesnt Have Enough Data, Amazingly, to Stop Explicit Content Barrons.com
01:27PM  Buy Apple (AAPL) Stock Up 22% in 2019 Before Streaming Video Launch? Zacks
01:00PM  Facebook fixes glitch that exposed millions of user passwords to employees Reuters
12:42PM  Facebook acknowledges it stored millions of passwords in plain text for years after security researcher exposes issue. Associated Press
12:19PM  Facebook Stored Millions of User Passwords Improperly for Years TheStreet.com
12:12PM  Facebook admits storing millions of user passwords in plain text files for years The Independent
11:59AM  Facebook says issues fixed after finding user passwords in readable format Reuters
11:59AM  Facebook Is Dealing With Another Privacy Issue: Employees Could See Millions Of User Passwords Benzinga
11:58AM  Facebook stored passwords in plain text, accessible by em... CNBC Videos
11:56AM  Facebook Says Millions of Passwords Were Visible Internally Bloomberg
11:53AM  Facebook says issues fixed after finding user passwords in readable format Reuters
11:49AM  Facebook stored 'hundreds of millions' of passwords in plain text for years The Telegraph
11:37AM  Facebook employees had access to millions of user passwords CNBC
10:40AM  2020 hopeful Beto O'Rourke says he'd rather see Big Tech regulated than broken up CNBC
10:39AM  Amazon to Launch Mobile Ads, in a Threat to Google and Facebook Bloomberg
09:00AM  Tech Stocks in the News You Should Know ACCESSWIRE
08:54AM  Facebook explains why its A.I. didn't detect the New Zealand mosque shooting video CNBC
08:28AM  After Google, EUs Antitrust Sights May Turn to Amazon and Apple Bloomberg
06:43AM  Facebook admits New Zealand shooting video reveals gaps in its AI but pushes back on time-delay policy MarketWatch
06:00AM  Snap Stock Will Make a Strong Recovery Sooner Than You Think InvestorPlace
Mar-20-19 10:03PM  Lithuanian pleads guilty in U.S. to massive fraud against Google, Facebook Reuters
07:56PM  4 Stocks in Focus on World's Most Expensive Election Zacks
07:55PM  [$$] Lithuanian Man Pleads Guilty to $100 Million Fraud Against Google, Facebook The Wall Street Journal
07:21PM  Facebook Is More Than Just a Social Network, and Should Be Valued Accordingly TheStreet.com
07:01PM  [$$] The Internet and Evil The Wall Street Journal
06:35PM  Here's Why Nike (NKE) Stock Looks like a Buy Heading into Q3 Earnings Zacks
06:08PM  Instagram Takes the Next Step to Conquer "Social Shopping" Motley Fool
04:34PM  What's A Picture Worth? Analyst Says New Instagram Feature Could Be Valuable For Facebook Benzinga
02:43PM  Lithuanian pleads guilty in U.S. to massive fraud against Google, Facebook Reuters
02:00PM  How the industry could benefit from major players like the Facebook cryptocurrency Coin Rivet
01:16PM  FANG Stocks: What to Expect in 2019 Motley Fool
12:44PM  Notion that big tech won't work with military is untrue, ... CNBC Videos
12:16PM  Facebook's Oculus unveils new virtual reality headset CNBC Videos
12:14PM  The Venture-Capital Bubble Is Going to Burst Barrons.com
12:08PM  What Facebooks Privacy Pivot Could Mean for Its Stock Barrons.com
11:35AM  Facebook overhauls targeted ads after discrimination complaints CBS News Videos
11:00AM  Facebook's Oculus Launches PC-Connected Rift S to Replace Rift Bloomberg
11:00AM  Facebook shows it's still serious about virtual reality with new $399 headset CNBC
09:04AM  Here's what investors need to know about the political ca... CNBC Videos
08:52AM  Facebook to change its ad-targeting options to prevent di... CNBC Videos
08:34AM  EU Renews Calls to Facebook, Twitter to Fight Fake News Bloomberg
08:17AM  Facebook Is Looking to Get In on the Gaming Gold Rush Too TheStreet.com
06:00AM  Bull of the Day: Foot Locker, Inc. (FL) Zacks
05:59AM  Facebook agrees to advertising overhaul to settle U.S. discrimination suits Reuters
05:56AM  U.S. lawmaker says tech companies must quickly remove violent content after New Zealand Reuters
05:01AM  YouTubes Algorithm Isnt The Problem For Alphabet Stock Investors InvestorPlace
05:00AM  How Small Investors Can Play Lyft and Other IPOs Barrons.com
Mar-19-19 10:17PM  Father and son who fled Syria are buried in New Zealand Associated Press
09:35PM  Father and son who fled Syria are buried in New Zealand Associated Press
08:27PM  Facebook to revamp targeted ads to avoid discrimination CBS News Videos
08:25PM  U.S. lawmaker says tech companies must quickly remove violent content after New Zealand Reuters
07:44PM  [$$] House Seeks Answers From Tech CEOs Over Shooting Video The Wall Street Journal
06:41PM  Facebook agrees to advertising overhaul to settle U.S. discrimination suits Reuters
06:24PM  Facebook agrees to advertising overhaul to settle U.S. discrimination suits Reuters
06:22PM  UPDATE 1-Facebook agrees to advertising overhaul to settle U.S. discrimination suits CNBC
06:16PM  Trump: Social media sites discriminate against conservatives Associated Press
05:47PM  Facebook to overhaul ad targeting to prevent discrimination Associated Press
05:31PM  U.S. lawmaker says tech companies must quickly remove violent content after New Zealand Reuters
05:30PM  Why Facebook didn't block live New Zealand shooting video Associated Press
05:17PM  Why Marijuana REITs Are One of the Best Investments Today InvestorPlace
05:12PM  U.S. lawmaker says tech companies must quickly remove violent content after New Zealand Reuters
05:08PM  Trump 2020 ad spending nearly doubles Democrats on Facebook, Google: Report Fox Business Videos
05:00PM  Congressman calls on tech CEOs to explain the spread of the mosque shooting video on their platforms CNBC
Facebook, Inc. provides various products to connect and share through mobile devices, personal computers, and other surfaces worldwide. The company's products include Facebook that enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers; Instagram, a community for sharing photos, videos, and messages; Messenger, a messaging application for people to connect with friends, family, groups, and businesses across platforms and devices; and WhatsApp, a messaging application for use by people and businesses to communicate in a private way. It also provides Oculus, a hardware, software, and developer ecosystem, which allows people to come together and connect with each other through its Oculus virtual reality products. As of December 31, 2018, it had approximately 1.52 billion daily active users. The company was founded in 2004 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stretch ColinVP and General CounselMar 20Sale161.50750121,125103,872Mar 22 06:54 PM
Sandberg SherylChief Operating OfficerMar 13Sale173.2455,0009,528,2961,272,127Mar 15 06:19 PM
Stretch ColinVP and General CounselMar 13Sale172.35750129,263104,622Mar 15 06:20 PM
Cox Christopher KChief Product OfficerMar 11Sale173.115,300917,47188,741Mar 13 06:42 PM
Stretch ColinVP and General CounselMar 06Sale172.60750129,450105,372Mar 08 06:38 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsFeb 28Sale162.3710,0001,623,70058,970Mar 04 06:33 PM
Stretch ColinVP and General CounselFeb 27Sale162.91750122,183106,122Feb 28 07:27 PM
Sandberg SherylChief Operating OfficerFeb 26Sale164.9455,0009,071,4551,272,127Feb 28 08:03 PM
Wehner David M.Chief Financial OfficerFeb 25Sale164.904,979821,03749,156Feb 27 07:26 PM
Taylor Susan J.S.Chief Accounting OfficerFeb 20Sale162.021,442233,6330Feb 20 07:30 PM
Stretch ColinVP and General CounselFeb 20Sale162.02750121,515106,872Feb 20 07:32 PM
Wehner David M.Chief Financial OfficerFeb 19Sale160.354,979798,38354,135Feb 20 07:29 PM
Cox Christopher KChief Product OfficerFeb 19Sale160.355,300849,85594,041Feb 20 07:36 PM
Sandberg SherylChief Operating OfficerFeb 15Option Exercise0.0073,32701,276,801Feb 19 07:08 PM
Wehner David M.Chief Financial OfficerFeb 15Option Exercise0.0037,786063,788Feb 20 07:29 PM
Taylor Susan J.S.Chief Accounting OfficerFeb 15Option Exercise0.002,24901,678Feb 20 07:30 PM
Stretch ColinVP and General CounselFeb 15Option Exercise0.0026,1660109,261Feb 20 07:32 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsFeb 15Option Exercise0.0019,030072,836Feb 20 07:34 PM
Cox Christopher KChief Product OfficerFeb 15Option Exercise0.0045,125085,331Feb 20 07:36 PM
Schroepfer Michael ToddChief Technology OfficerFeb 15Option Exercise0.0054,5510334,414Feb 20 07:38 PM
Sandberg SherylChief Operating OfficerFeb 14Sale163.6855,0009,002,1751,235,157Feb 19 07:08 PM
Stretch ColinVP and General CounselFeb 13Sale165.38750124,03593,180Feb 15 06:20 PM
Stretch ColinVP and General CounselFeb 06Sale171.21750128,40893,930Feb 08 06:17 PM
Wehner David M.Chief Financial OfficerJan 31Sale165.594,761788,37439,191Feb 01 06:48 PM
Stretch ColinVP and General CounselJan 30Sale150.009,0001,350,00094,680Feb 01 06:36 PM
Cox Christopher KChief Product OfficerJan 30Sale150.005,300795,00058,484Feb 01 06:35 PM
Sandberg SherylChief Operating OfficerJan 23Sale144.9355,0007,970,9731,235,157Jan 25 07:53 PM
Cox Christopher KChief Product OfficerJan 15Sale150.0715,9002,386,14563,784Jan 17 06:59 PM
Sandberg SherylChief Operating OfficerJan 08Sale141.6655,0007,791,0371,235,157Jan 10 06:11 PM
Sandberg SherylChief Operating OfficerDec 27Sale132.1155,0007,266,1111,235,157Dec 28 06:29 PM
Taylor Susan J.S.Chief Accounting OfficerDec 10Sale139.602,112294,8350Dec 12 06:43 PM
Sandberg SherylChief Operating OfficerDec 10Sale140.9455,0007,751,7661,235,157Dec 12 06:45 PM
Taylor Susan J.S.Chief Accounting OfficerNov 27Sale135.812,268308,0172,112Nov 29 06:46 PM
Sandberg SherylChief Operating OfficerNov 27Sale135.1255,0007,431,6641,235,157Nov 29 06:44 PM
Schroepfer Michael ToddChief Technology OfficerNov 21Sale135.8938,1855,188,845473,930Nov 26 07:22 PM
Taylor Susan J.S.Chief Accounting OfficerNov 19Sale137.502,112290,4004,380Nov 19 08:20 PM
Wehner David M.Chief Financial OfficerNov 16Sale141.104,761671,77781,097Nov 19 08:22 PM
Cox Christopher KChief Product OfficerNov 15Option Exercise0.0045,1230140,684Nov 19 08:15 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsNov 15Option Exercise0.0027,741052,520Nov 19 08:17 PM
Stretch ColinVP and General CounselNov 15Option Exercise0.0026,1670105,319Nov 19 08:18 PM
Taylor Susan J.S.Chief Accounting OfficerNov 15Option Exercise0.002,25006,927Nov 19 08:20 PM
Wehner David M.Chief Financial OfficerNov 15Option Exercise0.0037,786090,532Nov 19 08:22 PM
Schroepfer Michael ToddChief Technology OfficerNov 15Option Exercise0.0045,1230615,541Nov 19 08:23 PM
Sandberg SherylChief Operating OfficerNov 15Option Exercise0.0063,90401,243,343Nov 16 07:13 PM
Sandberg SherylChief Operating OfficerNov 14Sale143.3455,0007,883,6301,202,939Nov 16 07:13 PM
Schroepfer Michael ToddChief Technology OfficerNov 13Sale142.9238,1645,454,506676,627Nov 15 07:37 PM
Stretch ColinVP and General CounselNov 07Sale151.57750113,67890,144Nov 07 06:36 PM
Cox Christopher KChief Product OfficerNov 06Sale150.052,000300,102113,837Nov 07 06:34 PM
Cox Christopher KChief Product OfficerNov 05Sale150.093,300495,309115,837Nov 05 06:37 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsNov 01Sale151.521,560236,37135,465Nov 05 06:39 PM
Stretch ColinVP and General CounselOct 31Sale155.00750116,25090,894Oct 31 06:43 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsOct 29Sale148.392,648392,93737,025Oct 31 06:41 PM
Stretch ColinVP and General CounselOct 24Sale154.28750115,71091,644Oct 25 06:31 PM
Sandberg SherylChief Operating OfficerOct 23Sale152.9055,0008,409,6631,537,239Oct 25 06:34 PM
Stretch ColinVP and General CounselOct 17Sale160.00750120,00092,394Oct 19 06:06 PM
Cox Christopher KChief Product OfficerOct 15Sale153.445,300813,248119,137Oct 17 06:03 PM
Stretch ColinVP and General CounselOct 10Sale157.12750117,84093,144Oct 12 06:16 PM
Sandberg SherylChief Operating OfficerOct 10Sale154.8755,0008,517,8051,537,239Oct 12 06:26 PM
Schroepfer Michael ToddChief Technology OfficerOct 09Sale159.0438,1056,060,294617,657Oct 11 06:23 PM
Stretch ColinVP and General CounselOct 03Sale160.00750120,00093,894Oct 03 06:21 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsOct 01Sale163.023,125509,43834,375Oct 03 06:19 PM
Sandberg SherylChief Operating OfficerSep 27Sale169.6755,0009,331,7461,537,239Sep 28 08:06 PM
Stretch ColinVP and General CounselSep 26Sale164.29750123,21894,644Sep 26 06:21 PM
Cox Christopher KChief Product OfficerSep 24Sale164.355,300871,068124,437Sep 26 06:20 PM
Stretch ColinVP and General CounselSep 19Sale160.03750120,02395,394Sep 20 06:52 PM
Stretch ColinVP and General CounselSep 12Sale163.25750122,43896,144Sep 13 06:15 PM
Schroepfer Michael ToddChief Technology OfficerSep 11Sale166.1138,0856,326,417589,506Sep 13 06:17 PM
Sandberg SherylChief Operating OfficerSep 11Sale166.0755,0009,134,0651,537,239Sep 13 06:19 PM
Stretch ColinVP and General CounselSep 05Sale168.85750126,63896,894Sep 06 06:46 PM
Cox Christopher KChief Product OfficerSep 04Sale171.285,300907,786129,737Sep 06 06:44 PM
Zuckerberg MarkCOB and CEOAug 31Sale175.69195,00034,259,4470Sep 04 07:03 PM
Zuckerberg MarkCOB and CEOAug 30Sale178.29212,00037,798,2460Sep 04 07:03 PM
Zuckerberg MarkCOB and CEOAug 29Sale175.67212,00037,242,7510Aug 29 08:43 PM
Stretch ColinVP and General CounselAug 29Sale176.10750132,07597,644Aug 31 06:40 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsAug 29Sale176.2161,10310,766,94737,500Aug 31 06:42 PM
Sandberg SherylChief Operating OfficerAug 29Sale175.6755,0009,661,7931,537,239Aug 31 06:44 PM
Zuckerberg MarkCOB and CEOAug 28Sale177.00195,00034,515,8650Aug 29 08:43 PM
Zuckerberg MarkCOB and CEOAug 27Sale177.42195,00034,596,1850Aug 29 08:43 PM
Zuckerberg MarkCOB and CEOAug 24Sale174.12120,00020,894,0960Aug 27 06:35 PM
Zuckerberg MarkCOB and CEOAug 23Sale174.28143,21024,958,4790Aug 27 06:35 PM
Stretch ColinVP and General CounselAug 22Sale172.20750129,15098,394Aug 22 06:32 PM
Zuckerberg MarkCOB and CEOAug 22Sale173.05120,00020,766,0980Aug 22 06:34 PM
Zuckerberg MarkCOB and CEOAug 21Sale173.07120,00020,768,0500Aug 22 06:34 PM
Zuckerberg MarkCOB and CEOAug 20Sale172.55120,00020,705,7800Aug 22 06:34 PM
Zuckerberg MarkCOB and CEOAug 17Sale173.48157,30027,288,5370Aug 20 07:09 PM
Wehner David M.Chief Financial OfficerAug 16Sale180.209,5221,715,86476,808Aug 17 07:41 PM
Zuckerberg MarkCOB and CEOAug 16Sale177.56217,54938,627,3640Aug 20 07:07 PM
Wehner David M.Chief Financial OfficerAug 15Option Exercise0.0037,787091,004Aug 17 07:41 PM
Taylor Susan J.S.Chief Accounting OfficerAug 15Option Exercise0.002,25005,793Aug 17 07:38 PM
Schroepfer Michael ToddChief Technology OfficerAug 15Option Exercise0.0045,1250575,586Aug 16 06:46 PM
Sandberg SherylChief Operating OfficerAug 15Option Exercise0.0063,90101,545,424Aug 16 06:49 PM
Stretch ColinVP and General CounselAug 15Option Exercise0.0026,1670100,783Aug 17 07:37 PM
FISCHER DAVID B.VP Bus. & Marketing P'shipsAug 15Option Exercise0.0027,739097,314Aug 17 07:35 PM
Cox Christopher KChief Product OfficerAug 15Option Exercise0.0045,1250121,929Aug 17 07:33 PM
Zuckerberg MarkCOB and CEOAug 15Sale178.00210,00037,379,5420Aug 15 07:55 PM
Stretch ColinVP and General CounselAug 15Sale179.17750134,37885,615Aug 17 07:37 PM
Sandberg SherylChief Operating OfficerAug 14Sale180.7255,0009,939,4451,505,021Aug 16 06:49 PM
Schroepfer Michael ToddChief Technology OfficerAug 14Sale180.7238,0376,873,876561,335Aug 16 06:46 PM
Zuckerberg MarkCOB and CEOAug 14Sale180.72210,00037,951,8970Aug 15 07:53 PM
Zuckerberg MarkCOB and CEOAug 13Sale181.02210,00038,015,1710Aug 15 07:53 PM
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E15.93 EPS (ttm)5.53 Insider Own0.10% Shs Outstand701.01M Perf Week-0.35%
Market Cap61.79B Forward P/E7.02 EPS next Y12.56 Insider Trans-3.24% Shs Float701.01M Perf Month-0.56%
Income4.05B PEG0.91 EPS next Q2.43 Inst Own77.30% Short Float2.73% Perf Quarter34.42%
Sales15.28B P/S4.04 EPS this Y5.90% Inst Trans1.92% Short Ratio1.66 Perf Half Y0.88%
Book/sh8.81 P/B10.01 EPS next Y17.29% ROA11.80% Target Price97.66 Perf Year-0.18%
Cash/sh8.62 P/C10.23 EPS next 5Y17.52% ROE82.50% 52W Range58.59 - 95.30 Perf YTD37.54%
Dividend- P/FCF12.76 EPS past 5Y26.80% ROI16.70% 52W High-7.50% Beta1.70
Dividend %- Quick Ratio2.10 Sales past 5Y18.70% Gross Margin96.20% 52W Low50.45% ATR1.69
Employees8852 Current Ratio2.20 Sales Q/Q15.90% Oper. Margin34.00% RSI (14)51.83 Volatility1.50% 1.77%
OptionableYes Debt/Eq3.29 EPS Q/Q-2.20% Profit Margin26.50% Rel Volume0.64 Prev Close89.63
ShortableYes LT Debt/Eq3.21 EarningsJan 31 BMO Payout0.00% Avg Volume11.51M Price88.15
Recom2.40 SMA200.86% SMA500.35% SMA2006.81% Volume7,309,989 Change-1.65%
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Mar-21-19 10:03AM  Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition Zacks
07:30AM  Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week. Barrons.com
Mar-20-19 04:16PM  Amid Bristol-Starboard Duel Over Celgene, Here's What's Really Key Investor's Business Daily
11:24AM  Emergent Begins Phase III Study on Anthrax Vaccine AV7909 Zacks
08:55AM  Buy These 5 ROE Stocks as Stock Market Euphoria Continues Zacks
08:32AM  The Zacks Analyst Blog Highlights: Hilton, Xilinx, Quanta, Anthem and Celgene Zacks
Mar-19-19 09:33PM  Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle? Motley Fool
06:18PM  [$$] If This Is Failure, Show Me Success The Wall Street Journal
05:53PM  Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia Zacks
02:26PM  Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse Zacks
02:17PM  Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting. Barrons.com
01:14PM  Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat TheStreet.com
11:57AM  PhaseBio Stock Up on Positive Data From PB2452 Phase I Study Zacks
11:51AM  Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients Zacks
11:24AM  Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer TheStreet.com
10:48AM  Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk TheStreet.com
09:53AM  Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers TheStreet.com
09:52AM  Are Americans More Confident in 2019? 5 Top Picks Zacks
09:45AM  Bristol-Myers Squibb and Starboard Value square off over Celgene deal American City Business Journals
Mar-18-19 06:44PM  Bristol-Myers & Pfizer Release Phase IV Data on Eliquis Zacks
05:45PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
09:30AM  Is Celgene (CELG) Outperforming Other Medical Stocks This Year? Zacks
08:06AM  AstraZeneca Up This Year on New Drugs & Pipeline Progress Zacks
07:25AM  Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study Zacks
06:23AM  Bear of the Day: Gilead Sciences (GILD) Zacks
Mar-15-19 04:04PM  Roche Gets Approval for Label Expansion of MabThera in Europe Zacks
03:36PM  Top Ranked Value Stocks to Buy for March 14th Zacks
02:00PM  Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail? Motley Fool
12:04PM  Top Ranked Value Stocks to Buy for March 15th Zacks
11:38AM  AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag Zacks
11:25AM  PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y Zacks
05:05AM  J&J Seeks Approval for Darzalex in Expanded Patient Group Zacks
Mar-14-19 05:15PM  Washington Health Care Facilities Auth -- Moody's upgrades Fred Hutchinson Cancer Research Center (WA) to A2 from A3; outlook stable Moody's
04:24PM  Key Celgene Issue That Could 'Unnerve' Bristol Takeover Was Just Tossed Investor's Business Daily
11:20AM  Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why Zacks
11:13AM  Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up Zacks
09:32AM  U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug Reuters
09:09AM  U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid Reuters
Mar-13-19 05:31PM  5 Biotech Stocks to Keep an Eye on in 2019 GuruFocus.com
04:37PM  Celgenes Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says Barrons.com
04:17PM  Does This Celgene-Roche Approval Sweeten The Pot For Bristol? Investor's Business Daily
12:50PM  Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma Zacks
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
09:30AM  CELG vs. VRTX: Which Stock Is the Better Value Option? Zacks
09:11AM  Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals Zacks
08:54AM  Top Ranked Value Stocks to Buy for March 11th Zacks
Mar-12-19 04:59PM  How This Looming Patent Battle Could Challenge Bristol-Celgene Deal Investor's Business Daily
04:30PM  Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer Business Wire
03:22PM  Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion Zacks
10:07AM  Celgene (CELG) Submits Application for MS Drug in Europe Zacks
09:59AM  Alnylam Files Application for Hypertension Candidate in UK Zacks
09:55AM  Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer Zacks
09:42AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
06:06AM  3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade Motley Fool
Mar-11-19 06:14PM  Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source Reuters
05:45PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
10:35AM  AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study Zacks
07:30AM  Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis Business Wire
02:28AM  Here's Why bluebird bio Gained 16.3% in February Motley Fool
Mar-09-19 06:00AM  3 Top Biotech Stocks to Buy in March Motley Fool
Mar-08-19 11:04AM  Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat Zacks
10:10AM  Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up Zacks
10:04AM  Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4 Zacks
12:49AM  [$$] Why old-school asset managers are copying the activists Financial Times
Mar-07-19 10:20PM  NanoString Technologies Inc (NSTG) Q4 2018 Earnings Conference Call Transcript Motley Fool
11:58AM  I Like the Long Side of Bristol-Myers Squibb TheStreet.com
09:06AM  Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 Zacks
07:56AM  Top Ranked Value Stocks to Buy for March 7th Zacks
Mar-06-19 08:22PM  Bristol-Myers CEO: Celgene merger will yield 6 products in 24 months CNBC Videos
05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
04:09PM  Bristol Slides As Drug Giant Defends Its Looming Celgene Takeover Investor's Business Daily
12:20PM  Bristol-Myers defends Celgene bet as investor criticism grows Reuters
10:26AM  Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More Zacks
10:21AM  Zacks.com featured highlights include: Best Buy, Celgene, General Motors, Facebook and CBRE Zacks
10:14AM  Bristol-Myers says Celgene deal is 'best path' as investor opposition mounts Reuters
08:11AM  Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance CNBC
07:06AM  Celgene buy best path forward, Bristol-Myers says Reuters
Mar-05-19 10:02PM  [$$] Bristol-Myers Squibb defends Celgene takeover as best path Financial Times
09:22AM  Why Geron Skyrocketed 27% in February Motley Fool
08:32AM  5 ROE Stocks to Profit as Trade Talks Enter Decisive Phase Zacks
07:30AM  U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis Business Wire
07:15AM  3 Best Biotech Bargain Stocks on the Market Right Now Motley Fool
Mar-04-19 11:38PM  Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks Zacks
07:23PM  [$$] Celgene Odds Are in Investors Favor The Wall Street Journal
05:15PM  Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion Zacks
01:24PM  Bristol-Myers Squibb's $74B deal for Celgene criticized, called risky American City Business Journals
11:26AM  Watch CNBC's exclusive interview with Jim Woolery CNBC Videos
07:12AM  S&P 500 Closes Above 2,800 After Nearly 4 Months: 5 Picks Zacks
Mar-01-19 04:52PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
04:25PM  Bristol Investors Face Tough Road In Quashing Celgene Deal: Analyst Investor's Business Daily
04:02PM  The Bristol-MyersSquibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen Barrons.com
02:20PM  Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up Zacks
02:18PM  Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales Zacks
02:03PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
11:59AM  Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018 Zacks
10:17AM  Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up Zacks
09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
09:33AM  Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales Zacks
09:22AM  Fridays Vital Data: Square, Southwest Airlines and Celgene InvestorPlace
09:16AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA to treat various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaborations with Skyhawk Therapeutics, Inc., Dragonfly Therapeutics, Inc., Obsidian Therapeutics, Philogen S.p.A., and Kyn Therapeutics. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
ACT AdvisorShares Vice ETF daily Stock Chart
ACT [NASD]
AdvisorShares Vice ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-0.92%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month0.94%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter14.48%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.69 Perf Half Y-4.75%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year0.34%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range20.88 - 27.73 Perf YTD17.69%
Dividend0.37 P/FCF- EPS past 5Y- ROI- 52W High-9.18% Beta-
Dividend %1.47% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low20.62% ATR0.28
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)56.92 Volatility1.26% 0.97%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.88 Prev Close25.62
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume5.18K Price25.18
Recom- SMA20-0.16% SMA504.70% SMA2000.63% Volume14,919 Change-1.70%
Mar-19-19 01:00PM  Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs Zacks
Mar-14-19 08:00AM  Marijuana Fund Smokes Competition Amid Flurry Of Positive News Investor's Business Daily
Mar-12-19 02:30PM  US Marijuana Market Warms Up to Merger Deals: ETFs in Focus Zacks
Mar-04-19 12:51PM  7 Consumer Staples ETFs to Buy Now InvestorPlace
Mar-01-19 01:00PM  Why Marijuana ETFs & Stocks Have More Room to Run Zacks
Feb-25-19 08:00AM  New ETFs To Consider, Plus Second Marijuana Play On The Way? Investor's Business Daily
Feb-21-19 02:31PM  ETFs and Stocks to Tap the Marijuana Boom Zacks
Feb-06-19 11:10AM  AdvisorShares Files for Marijuana ETF Zacks
11:07AM  Marijuana ETF Tops $1 Billion in AUM ETF Trends
Jan-30-19 05:32PM  AdvisorShares Eyes Marijuana ETF Listing Benzinga
Jan-29-19 04:40PM  Marijuana ETFs to Access Growing Cannabis Outlook ETF Trends
03:40PM  Marijuana ETF YOLO is in the Works ETF Trends
Dec-27-18 01:00PM  AdvisorShares Announces December 2018 Distributions PR Newswire
Nov-28-18 10:50AM  Another Cannabis ETF on the Way Zacks
Nov-26-18 12:16PM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool
Nov-06-18 08:00AM  Will Cannabis ETFs be on a High Again? Zacks
Oct-15-18 08:02AM  This Sin-Stock ETF's Marijuana Moves Have Missed the Mark Motley Fool
Oct-11-18 01:45PM  Fans of Tilray Stock Ought to Ride MJ to Success InvestorPlace
Sep-17-18 08:52AM  The Zacks Analyst Blog Highlights: United States Gasoline, Invesco Dynamic Building & Construction, Materials Select Sector SPDR Fund and AdvisorShares VICE Zacks
Sep-14-18 01:25PM  4 ETFs Set to Soar in the Aftermath of Hurricane Florence Zacks
Sep-12-18 12:00PM  Why Bausch Health Companies Inc. Stock Is Booming Today Motley Fool
Aug-21-18 10:18AM  5 Vice ETFs That Are Worth Sinning For InvestorPlace
Aug-17-18 07:31AM  If I Had to Buy 1 Stock in August, It Would Be This One Motley Fool
Aug-02-18 07:42PM  Allergan sues Pfizer over costs of opioid litigation Reuters
04:48PM  Allergan sues Pfizer over costs of opioid litigation Reuters
04:16PM  Allergan sues Pfizer over costs of opioid litigation Reuters
02:31PM  Allergan Sues Pfizer Over Damages in Opioid Litigation Bloomberg
11:55AM  Marijuana ETFs: The Pros and Cons Investopedia
Jul-26-18 10:02AM  3 Charts Suggest It's Time to Invest in Sin Stocks Investopedia
Jul-02-18 11:26PM  Here Are the Only Two Marijuana ETFs U.S. Investors Need Consider InvestorPlace
Jun-21-18 10:55AM  Canada Legalizes Marijuana: Two ETFs to Tap the Boom Zacks
Jun-20-18 02:12PM  Marijuana ETFs Grow on Canadian Parliaments Ruling ETF Trends
May-21-18 03:44PM  Marijuana Stocks: This Unique Weed Merger Offers Tech, Eyes U.S. Listing Investor's Business Daily
May-17-18 12:40PM  Marijuana ETFs Experience Setbacks Investopedia
May-07-18 03:26PM  3 Marijuana ETFs for Everyday Investors to Play the Cannabis Movement InvestorPlace
Apr-20-18 10:54AM  4/20: Marijuana, hemp legalization moves ahead in many states Yahoo Finance Video
09:07AM  Futures point slightly lower, Trump bashes OPEC over oil prices Yahoo Finance
Feb-16-18 03:31PM  United Therapeutics reaches patent settlement with Actavis American City Business Journals
03:16PM  United Therapeutics settles patent litigation over $157M drug American City Business Journals
Feb-14-18 09:58AM  Marijuana and Blockchain: 2018's Hottest New ETFs Zacks
Feb-06-18 12:20PM  Allergan CEO: We Are Staying in Ireland TheStreet.com
Feb-01-18 08:49AM  Allergan to pay Israel's Teva Pharm $700 million to settle dispute Reuters
Jan-17-18 12:14AM  [$$] Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant The Wall Street Journal
Jan-16-18 06:02PM  [$$] Judge Signals He Will Approve Settlement Between Allergan Shareholders and Pershing, Valeant The Wall Street Journal
Jan-11-18 04:25PM  What Investors Need to Know About Marijuana ETFs Zacks
03:33PM  Ackmans Pershing Square cuts hedge-fund fees due to lawsuit settlement MarketWatch
Jan-10-18 09:52AM  'New' Fund Soars To Record High: Is Cannabis The New Bitcoin? Investor's Business Daily
Jan-04-18 04:12PM  Pot Stock Plays Fall, But Here's Why Jeff Sessions May Not Matter Much Investor's Business Daily
Dec-30-17 10:16AM  Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million Forbes
Dec-29-17 11:31PM  [$$] Pershing Square, Valeant to Pay $290 Million to Settle Allergan Suit The Wall Street Journal
02:16PM  Pershing Square, Valeant arrive at settlement split for Allergan lawsuit Reuters
01:28PM  Pershing Square, Valeant to Pay $290 Million to End Lawsuit Bloomberg
01:07PM  Valeant says parties in Allergan litigation have agreed to resolve claims of $290 million MarketWatch
Dec-28-17 02:27PM  Rush for Marijuana ETFs Getting Stronger Zacks
Dec-26-17 12:44AM  [$$] Judge Sides Against Ackman and Valeant in Preliminary Allergan Ruling The Wall Street Journal
Dec-20-17 08:00AM  This Week's ETF Launches: Introducing the First Quadruple-Leveraged Products ETF Database
Dec-13-17 02:58PM  Sin Is In With New Vice ETF ETF Trends
The investment seeks long-term capital appreciation. The fund is an actively-managed exchange-traded fund that invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from tobacco and alcoholic beverages and companies that derive at least 50% of their net revenue from the marijuana and hemp industry or have at least 50% of their company assets dedicated to lawful research and development of cannabis or cannabinoid-related products. It will invest primarily in U.S. exchange listed equity securities, including common and preferred stock and ADRs.
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-15.37 Insider Own0.10% Shs Outstand335.20M Perf Week-1.29%
Market Cap50.05B Forward P/E8.52 EPS next Y17.52 Insider Trans0.83% Shs Float331.74M Perf Month9.30%
Income-5157.10M PEG- EPS next Q3.55 Inst Own89.20% Short Float1.05% Perf Quarter9.33%
Sales15.79B P/S3.17 EPS this Y24.90% Inst Trans-0.39% Short Ratio1.21 Perf Half Y-20.60%
Book/sh194.25 P/B0.77 EPS next Y7.06% ROA-4.80% Target Price184.29 Perf Year-8.80%
Cash/sh5.69 P/C26.24 EPS next 5Y4.89% ROE-7.40% 52W Range125.84 - 197.00 Perf YTD11.70%
Dividend2.96 P/FCF11.54 EPS past 5Y-36.00% ROI-4.80% 52W High-24.21% Beta1.33
Dividend %1.98% Quick Ratio1.00 Sales past 5Y43.40% Gross Margin86.10% 52W Low18.64% ATR3.48
Employees16900 Current Ratio1.10 Sales Q/Q-5.70% Oper. Margin-38.30% RSI (14)52.25 Volatility2.06% 2.50%
OptionableYes Debt/Eq0.37 EPS Q/Q-769.60% Profit Margin-32.60% Rel Volume0.79 Prev Close153.53
ShortableYes LT Debt/Eq0.35 EarningsJan 29 BMO Payout- Avg Volume2.90M Price149.30
Recom2.10 SMA203.44% SMA502.88% SMA200-9.70% Volume2,277,464 Change-2.76%
Mar-20-19Initiated SunTrust Buy $178
Jan-31-19Downgrade Credit Suisse Outperform → Neutral
Jan-30-19Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-30-19Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-09-18Resumed Guggenheim Buy
Apr-24-18Resumed Citigroup Buy $200
Apr-23-18Resumed Evercore ISI Outperform
Apr-17-18Initiated Stifel Hold $192
Feb-23-18Initiated SunTrust Buy $200
Feb-07-18Reiterated Leerink Partners Outperform $237 → $242
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-27-17Resumed Leerink Partners Outperform $237
Nov-02-17Reiterated RBC Capital Mkts Outperform $250 → $221
Oct-19-17Reiterated RBC Capital Mkts Outperform $277 → $250
Oct-17-17Reiterated UBS Buy $275 → $255
Oct-02-17Reiterated Barclays Equal Weight
Sep-25-17Reiterated RBC Capital Mkts Outperform $285 → $277
Sep-20-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Neutral $231
Mar-22-19 08:31PM  Allergan promises independent board chair in next leadership change Reuters
06:19PM  Allergan promises independent board chair in next leadership change Reuters
05:44PM  Allergan plans independent board chairman Reuters
Mar-21-19 09:00AM  CoolSculpting® and Sonja Morgan Talk Bikini Denial Just In Time For Summer PR Newswire
08:19AM  Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus Zacks
Mar-20-19 03:25PM  NASH, Allergies and Beauty Stocks: Invest or Not? Zacks
02:55PM  Allergan Stock Wont Benefit From a Breakup, Analyst Says Barrons.com
01:09PM  10 Stocks on the Rise Heading Into the Second Quarter InvestorPlace
11:10AM  Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan Zacks
10:00AM  CoolSculpting® and Sonja Morgan Partner to Talk Bikini Denial PR Newswire
08:00AM  Here are the biggest analyst calls of the day: Lyft, Monster, FedEx, Rockwell Automation & more CNBC
Mar-19-19 11:51AM  Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients Zacks
Mar-18-19 01:36PM  Big Pharma Earnings Might Not Be as Good as They Look Barrons.com
09:54AM  Group with consumer-friendly vibe pushes drugmakers' message Associated Press
09:01AM  The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J Zacks
07:30AM  Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients PR Newswire
Mar-15-19 10:31AM  Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others Zacks
Mar-14-19 03:12PM  5 Undervalued Stocks to Invest In InvestorPlace
07:30AM  Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting PR Newswire
Mar-12-19 10:20AM  Allergan Announces FDA Acceptance of Migraine Candidate NDA Zacks
Mar-11-19 03:41PM  Allergan Stock Could Get a Boost From a Company Breakup, Analyst Says Barrons.com
09:40AM  Is Allergan (AGN) a Worthy Pick ForValue Investors Now? Zacks
07:30AM  Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine PR Newswire
Mar-10-19 09:19AM  Did Changing Sentiment Drive Allergans (NYSE:AGN) Share Price Down A Worrying 51%? Simply Wall St.
Mar-09-19 10:03AM  [$$] Why Allergan Shareholders Love Bad News The Wall Street Journal
Mar-08-19 02:22PM  Allergan Stocks Comeback Has Stalled, but CEO Brent Saunders Is Buying Barrons.com
Mar-07-19 04:53PM  Why News From J&J, Allergan Could Be A Boon For This Biotech Stock Investor's Business Daily
04:20PM  Could Kroger Lose the Grocery Wars Over This Challenge? TheStreet.com
01:20PM  Activists Aim to Eliminate Dual Role for Allergan CEO Saunders TheStreet.com
12:17PM  Allergan Stock Is Up, but Investors Are Worried About Its Drug Pipeline Barrons.com
11:37AM  US STOCKS-Dovish ECB stance pushes Wall St to fourth day of losses Reuters
11:28AM  Appaloosa steps up pressure on Allergan after failed drug trials Reuters
11:06AM  Appaloosa steps up pressure on Allergan after failed depression drug trials Reuters
10:54AM  Allergan's Depression Drug Letdown Largely Expected: Analysts Focus On Remainder Of Pipeline Benzinga
10:20AM  Allergan Rises After FDA Accepts License Applications for Botox Supplements TheStreet.com
08:48AM  Allergan's Depression Candidate Fails in Studies, Stock Down Zacks
08:00AM  FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity PR Newswire
07:47AM  Stocks making the biggest moves premarket: Allergan, General Electric, Qualcomm & more CNBC
03:29AM  Stocks - Kroger Plunges in Premarket, American Eagle Outfitters, Allergan Drop Investing.com
Mar-06-19 07:42PM  Today's After-Hours News: Allergan and American Eagle Are Trading Lower Motley Fool
05:02PM  Stocks making the biggest moves after hours: American Eagle, Allergan and more CNBC
04:28PM  Allergan stock falls after depression study fails MarketWatch
04:17PM  Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD) PR Newswire
12:54PM  Stocks Moving After Hours: Barnes & Noble, Rosetta Stone, American Eagle, GE Investing.com
08:50AM  J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression Zacks
Mar-04-19 10:12AM  Okta (OKTA) to Report Q4 Earnings: How Are Things Shaping Up? Zacks
07:30AM  Allergan to Present at The Cowen and Company 39th Annual Health Care Conference PR Newswire
Mar-01-19 07:30AM  Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C. PR Newswire
Feb-28-19 11:22PM  Editas Medicine Inc (EDIT) Q4 2018 Earnings Conference Call Transcript Motley Fool
03:02PM  Allergan shareholder Chevedden backs Appaloosa's proposal to split CEO-chairman role Reuters
02:18PM  Allergan shareholder Chevedden backs Appaloosa's proposal to split CEO-chairman role Reuters
Feb-27-19 07:19AM  Editas (EDIT) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-21-19 09:47AM  2 Frustrating Flops, Plus Welcome to the Wrinkle Wars Motley Fool
07:20AM  Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-20-19 09:08AM  Allergan Responds to Investor's Call for CEO/Chair Role Split Zacks
Feb-19-19 04:05PM  Allergan should explore selling itself: Appaloosa's Tepper Reuters
03:32PM  FINAL DEADLINE ALERT: Lead Plaintiff Deadline - February 19, 2019 - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) ACCESSWIRE
02:55PM  CLASS ACTION UPDATE for ARLO, AGN, DXC and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:00PM  Allergan Responds to Public Shareholder Letter PR Newswire
12:32PM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline -- February 19, 2019 ACCESSWIRE
11:16AM  Appaloosa's Tepper says Allergan should consider selling itself Reuters
10:33AM  CLASS ACTION UPDATE for DBVT, AGN, SVXY and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:23AM  CLASS ACTION UPDATE for GS, XRAY, NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  Dentsply Sirona, Inc. (XRAY), The Goldman Sachs Group, Inc. (GS), Allergan plc (AGN) & JA Solar Holdings Co. Ltd. (JASO): Bronstein, Gewirtz & Grossman, LLC Announces Final Deadline GlobeNewswire
07:00AM  Robert J. Hugin Appointed to Allergan Board of Directors PR Newswire
07:00AM  Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN GlobeNewswire
Feb-18-19 10:50PM  ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Allergan plc. - AGN Business Wire
04:39PM  FINAL DEADLINE ALERT - February 19, 2019 - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) and Lead Plaintiff Deadline ACCESSWIRE
12:38PM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) and Lead Plaintiff Deadline - February 19, 2019 ACCESSWIRE
12:00PM  DEADLINE TOMORROW for GS, XRAY, NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:34AM  Dentsply Sirona, Inc. (XRAY), The Goldman Sachs Group, Inc. (GS), Allergan plc (AGN) & JA Solar Holdings Co. Ltd. (JASO): Bronstein, Gewirtz & Grossman, LLC Announces Final Deadline ACCESSWIRE
08:00AM  CLASS ACTION UPDATE for XRAY, DBVT, AGN and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Feb-17-19 05:00PM  CLASS ACTION UPDATE for DNKEY, YOGA, AGN and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:00AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of XRAY, AGN, ALKS and SVXY GlobeNewswire
07:12AM  CLASS ACTION UPDATE for XRAY, NVDA, AGN and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Feb-15-19 10:50PM  ALLERGAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Allergan plc. - AGN Business Wire
05:48PM  Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
01:15PM  CLASS ACTION UPDATE for ARLO, AGN and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:55PM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline - February 19, 2019 ACCESSWIRE
12:29PM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline - February 19, 2019 ACCESSWIRE
10:15AM  CLASS ACTION UPDATE for AGN, ATVI, TYME and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:55AM  Dentsply Sirona, Inc. (XRAY), The Goldman Sachs Group, Inc. (GS) & Allergan plc (AGN): Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
07:30AM  Allergan to Present at The 8th Annual SVB Leerink Global Healthcare Conference PR Newswire
Feb-14-19 03:50PM  CLASS ACTION UPDATE for ARLO, SOGO, NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:33PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline AGN GlobeNewswire
03:01PM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline - February 19, 2019 ACCESSWIRE
02:04PM  CLASS ACTION UPDATE for ARLO, AGN, ALKS and MKL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:00PM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline - February 19, 2019 ACCESSWIRE
12:03PM  FDA Panel Nod for J&J's Esketamine Is Good News for Allergan, Vistagen GuruFocus.com
10:02AM  Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks
08:41AM  Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down Zacks
07:00AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of GS, XRAY, NVDA and AGN GlobeNewswire
Feb-13-19 08:00PM  CLASS ACTION UPDATE for SOGO, PRGO, AGN and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
05:17PM  Why Ironwood's Shares Climbed 11.7% on Wednesday Motley Fool
03:57PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SOGO, PRGO, AGN and ALKS GlobeNewswire
01:29PM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline - February 19, 2019 ACCESSWIRE
10:28AM  J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod Zacks
10:19AM  CLASS ACTION UPDATE for YOGA, YRCW, IMMU and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Feb-12-19 10:50PM  ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. - AGN GlobeNewswire
07:00PM  CLASS ACTION UPDATE for GS, XRAY, NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUNDERS BRENT LChairman, President and CEOMar 07Buy143.671,760252,858170,666Mar 07 03:19 PM
WALSH MATTHEW MEVP, Chief Financial OfficerNov 16Buy157.001,000157,00026,416Nov 19 07:22 PM
COUGHLIN CHRISTOPHER JDirectorSep 06Buy190.6410,0001,906,39416,431Sep 07 08:31 AM
Boccuzi Joseph HDirectorAug 30Buy190.59900171,5313,885Sep 04 05:06 PM
FREYMAN THOMAS CDirectorAug 30Buy190.691,100209,7592,658Sep 04 05:07 PM
Basgoz NesliDirectorAug 30Sale190.051,055200,5037,359Sep 04 05:08 PM
Basgoz NesliDirectorAug 10Option Exercise81.161,889153,3119,248Aug 14 05:32 PM
Meury WilliamEVP & Chief Commercial OfficerMay 17Option Exercise68.1121,2521,447,47440,154May 21 05:21 PM
Meury WilliamEVP & Chief Commercial OfficerMay 17Sale154.5924,4253,775,86115,729May 21 05:21 PM
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E87.82 EPS (ttm)2.07 Insider Own0.10% Shs Outstand254.88M Perf Week-3.49%
Market Cap46.27B Forward P/E28.69 EPS next Y6.33 Insider Trans-60.48% Shs Float254.63M Perf Month-0.84%
Income536.40M PEG1.60 EPS next Q0.97 Inst Own97.10% Short Float1.46% Perf Quarter14.41%
Sales3.05B P/S15.18 EPS this Y99.10% Inst Trans0.93% Short Ratio2.52 Perf Half Y2.79%
Book/sh17.40 P/B10.43 EPS next Y54.62% ROA43.80% Target Price209.11 Perf Year6.57%
Cash/sh12.43 P/C14.60 EPS next 5Y55.04% ROE67.50% 52W Range144.07 - 195.81 Perf YTD9.55%
Dividend- P/FCF39.38 EPS past 5Y23.90% ROI11.20% 52W High-7.29% Beta1.66
Dividend %- Quick Ratio3.30 Sales past 5Y20.30% Gross Margin86.60% 52W Low26.00% ATR3.85
Employees2500 Current Ratio3.40 Sales Q/Q33.50% Oper. Margin20.80% RSI (14)44.15 Volatility1.96% 2.07%
OptionableYes Debt/Eq0.13 EPS Q/Q-109.60% Profit Margin68.80% Rel Volume1.09 Prev Close182.56
ShortableYes LT Debt/Eq0.13 EarningsFeb 05 AMC Payout0.00% Avg Volume1.47M Price181.53
Recom1.90 SMA20-1.91% SMA50-2.45% SMA2003.16% Volume1,603,043 Change-0.56%
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Mar-21-19 06:00AM  CRISPR and Vertex- Front-Runners in Gene-Therapy MoneyShow
Mar-19-19 04:31PM  Biotech Giant Tumbles On Downgrade Amid Payer Pushback In Europe Investor's Business Daily
Mar-13-19 05:31PM  5 Biotech Stocks to Keep an Eye on in 2019 GuruFocus.com
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
09:30AM  CELG vs. VRTX: Which Stock Is the Better Value Option? Zacks
Mar-12-19 05:07AM  Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations Business Wire
Mar-11-19 01:41PM  Mass. firms riding bull market to nearly $1 trillion in gains American City Business Journals
Mar-10-19 07:11PM  Why Vertex's Dilemma Makes It the Best Biotech Stock to Buy Now Motley Fool
Mar-07-19 01:38PM  Top Research Reports for Amazon, Berkshire Hathaway & Thermo Fisher Zacks
09:31AM  Why Is Vertex (VRTX) Down 0.7% Since Last Earnings Report? Zacks
08:40AM  Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed Zacks
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
12:24PM  Vertex cystic fibrosis triple combo therapy succeeds in important trials Reuters
12:15PM  4 Low-Priced Stocks Under $10 for 2019 InvestorPlace
09:32AM  CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Business Wire
08:15AM  Detailed Research: Economic Perspectives on KAR Auction Services, Spectrum Brands, Vertex Pharmaceuticals, The Kraft Heinz, comScore, and Retrophin What Drives Growth in Today's Competitive Landscape GlobeNewswire
08:09AM  Vertex's cystic fibrosis therapy meets goal of late-stage studies Reuters
04:43AM  Mass. life science leaders say outgoing FDA head was an 'advocate for modernization' American City Business Journals
Mar-05-19 06:00AM  3 Hot Stocks to Buy in March Motley Fool
Mar-01-19 07:18AM  5 Top Stocks to Buy in March Motley Fool
Feb-28-19 03:53PM  5 Pharmaceutical Stocks With Big Moats and Bridges Kiplinger
Feb-27-19 04:25PM  Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates Zacks
08:21AM  3 Arguments For and Against Buying GW Pharmaceuticals Motley Fool
Feb-26-19 10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
Feb-25-19 08:00AM  CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 GlobeNewswire
12:58AM  [$$] Crispr Therapeutics treats its first human with gene editing Financial Times
Feb-24-19 02:00PM  Could Vertex Pharmaceuticals Be a Millionaire-Maker Stock? Motley Fool
Feb-22-19 08:45AM  The Zacks Analyst Blog Highlights: Nike, 3M, Vertex, PepsiCo and Verisk Zacks
08:00AM  The Top 5 Biotech Stocks Are Facing Growth Challenges Are Any Immune? Investor's Business Daily
Feb-21-19 04:01PM  Vertex Appoints Lloyd Carney to its Board of Directors Business Wire
01:59PM  Top Stock Reports for Nike, 3M & Vertex Zacks
09:44AM  The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis Zacks
Feb-20-19 10:03AM  Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More Zacks
09:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Feb-17-19 09:12AM  3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys? Motley Fool
Feb-14-19 09:04AM  Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission Business Wire
Feb-13-19 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $20.1 million of Shares GuruFocus.com
11:26AM  Have Insiders Been Selling Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares? Simply Wall St.
Feb-11-19 08:05AM  Groupon (GRPN) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-10-19 09:00AM  This Is the Best Biotech Stock on the Market Motley Fool
Feb-08-19 10:53AM  Check Out These 7 Fast-Growing Stocks to Buy Today InvestorPlace
07:04AM  Factors Likely to Influence Cisco's (CSCO) Earnings in Q2 Zacks
05:07AM  Factors Expected to Influence Akamai's (AKAM) Q4 Earnings Zacks
Feb-07-19 03:33PM  Vertex Pharmaceuticals: New Drug, Same Great Growth Story Motley Fool
09:39AM  The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO Zacks
Feb-06-19 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $6 million of Shares GuruFocus.com
10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
10:12AM  Stocks Turn Lower, But These Top Stocks Break Out On Earnings Investor's Business Daily
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
08:10AM  Vertex Pharmaceuticals (VRTX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:28AM  Dow Jones Futures: Snap Soars, But These 4 Top Stocks Are Crossing Buy Points Investor's Business Daily
07:06AM  Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink Zacks
Feb-05-19 05:20PM  Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates Zacks
05:09PM  This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales Investor's Business Daily
04:19PM  Vertex: 4Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results Business Wire
02:30PM  Vertex Pharmaceuticals Incorporated to Host Earnings Call ACCESSWIRE
11:06AM  Vertex Earnings, Revenue beat in Q4 Investing.com
Feb-04-19 08:58AM  Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store? Zacks
08:55AM  Qorvo (QRVO) to Report Q3 Earnings: What's in the Cards? Zacks
Feb-01-19 09:48AM  6 Biotech Stocks to Watch Now Motley Fool
Jan-31-19 07:18PM  Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales? Zacks
07:35AM  Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-29-19 09:30PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
10:31AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
10:11AM  Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids Zacks
10:00AM  Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings? Zacks
Jan-28-19 09:17AM  Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene Business Wire
Jan-26-19 06:10PM  Is Vertex Pharmaceuticals a Buy? Motley Fool
Jan-25-19 10:20AM  Hot Stocks Boost USAA Aggressive Growth Investor's Business Daily
09:44AM  Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds Zacks
Jan-24-19 10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
08:00AM  Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors PR Newswire
08:00AM  Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors CNW Group
07:59AM  Stocks making the biggest moves premarket: Southwest, Apple, Ford Motor & more CNBC
Jan-23-19 06:39PM  [$$] Vertex Pharmaceuticals Fires Executive for Conduct Violation The Wall Street Journal
05:51PM  Vertex Pharmaceuticals fires executive for 'personal behavior' American City Business Journals
05:13PM  Vertex Pharma boots out COO for "personal behavior" violations Reuters
04:41PM  Vertex Pharma terminates interim CFO's employment for code violations Reuters
04:30PM  Vertex terminates COO for 'personal behavior' MarketWatch
04:05PM  Vertex Announces Departure of Ian Smith, Names Interim CFO Business Wire
10:31AM  Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:30AM  CELG or VRTX: Which Is the Better Value Stock Right Now? Zacks
09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
08:18AM  Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool
Jan-22-19 04:01PM  Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5 Business Wire
09:31AM  Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids Zacks
Jan-21-19 10:10AM  Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again Zacks
04:00AM  Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease Business Wire
Jan-12-19 12:00PM  Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
07:31AM  3 Biotech Stocks to Watch in 2019 Motley Fool
Jan-11-19 04:18PM  Stocks Pare Losses As Small Caps Lead; Why Netflix Led The IBD 50 Investor's Business Daily
04:14PM  Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence Investor's Business Daily
12:08PM  Vertex Pharmaceuticals Begins Forming A Base Investor's Business Daily Video
Jan-09-19 10:04AM  Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks
Jan-08-19 10:12AM  Is Vertex Pharmaceuticals Incorporateds (NASDAQ:VRTX) CEO Being Overpaid? Simply Wall St.
07:15AM  5 Things to Expect for Vertex Pharmaceuticals in 2019 Motley Fool
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
Jan-06-19 09:32AM  Outlook For Battered Biotech Stocks In 2019 Investopedia
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG, Arbor Biotechnologies, Inc., Moderna Therapeutics, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc., as well as Janssen Pharmaceuticals, Inc. and Merck KGaA. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parini MichaelEVP, CL&AOFeb 19Sale186.985,6241,051,58535,003Feb 21 04:26 PM
Silva Paul MSVP & Interim CFOFeb 19Sale186.972,812525,74717,759Feb 21 04:27 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 19Sale187.005,6241,051,71631,553Feb 21 04:21 PM
Kewalramani ReshmaEVP and CMOFeb 19Sale186.941,488278,16313,736Feb 21 04:22 PM
LEIDEN JEFFREY MCEO & PresidentFeb 19Sale186.9820,9973,926,113106,195Feb 21 04:24 PM
Silva Paul MSVP & Interim CFOFeb 11Sale180.164,215759,36720,571Feb 13 04:27 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 11Sale180.2133,0735,959,96938,864Feb 13 04:37 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale180.2232,9565,939,18837,177Feb 13 04:36 PM
Sachdev AmitEVP, CROFeb 11Sale180.0635,0956,319,21640,165Feb 13 04:40 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale180.24111,43120,083,804127,192Feb 13 04:39 PM
Silva Paul MSVP & Interim CFOFeb 06Option Exercise91.051,289117,36313,938Feb 07 04:04 PM
Silva Paul MSVP & Interim CFOFeb 06Sale193.001,289248,77712,649Feb 07 04:04 PM
Parini MichaelEVP, CL&AOFeb 04Option Exercise86.522,330201,59238,489Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Option Exercise88.494,126365,11741,443Feb 06 04:46 PM
Silva Paul MSVP & Interim CFOFeb 04Option Exercise86.5280969,99516,896Feb 06 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Option Exercise99.977,959795,65754,711Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Option Exercise88.904,097364,23548,817Feb 06 04:51 PM
Parini MichaelEVP, CL&AOFeb 04Sale189.192,330440,81336,159Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Sale189.194,126780,59839,113Feb 06 04:46 PM
LEIDEN JEFFREY MCEO & PresidentFeb 04Sale186.3532,2506,009,682124,865Feb 06 04:47 PM
Silva Paul MSVP & Interim CFOFeb 04Sale187.024,247794,27312,649Feb 06 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Sale186.2018,3093,409,08236,402Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Sale186.8612,7222,377,29638,037Feb 06 04:51 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Option Exercise131.892,125280,26641,238Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Option Exercise131.892,125280,26648,877Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Option Exercise155.573,668570,63143,277Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Sale193.482,125411,14539,113Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Sale193.482,125411,14546,752Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Sale195.003,668715,26039,609Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Option Exercise155.701,223190,42140,336Jan 22 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Sale194.621,223238,02039,113Jan 22 04:07 PM
Silva Paul MSVP & Corp ControllerJan 17Option Exercise90.623,007272,48217,376Jan 18 04:18 PM
Silva Paul MSVP & Corp ControllerJan 17Sale190.623,007573,18216,087Jan 18 04:18 PM
Parini MichaelEVP, CL&AOJan 14Option Exercise90.292,125191,86641,734Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 14Sale186.712,125396,75939,609Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 04Option Exercise122.454,250520,41343,859Jan 07 04:02 PM
Parini MichaelEVP, CL&AOJan 04Sale165.904,250705,07539,609Jan 07 04:02 PM
SACHS BRUCE IDirectorDec 06Option Exercise34.2410,000342,40023,011Dec 07 04:06 PM
Silva Paul MSVP & Corp ControllerDec 03Option Exercise86.5280969,99516,896Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerDec 03Sale186.52809150,89516,087Dec 04 04:04 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale163.7510016,37539,113Nov 19 05:23 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale163.75294,74946,752Nov 19 05:28 PM
Sachdev AmitEVP, CRONov 15Sale163.75619,98946,662Nov 19 05:34 PM
Parini MichaelEVP, CL&AONov 15Sale163.759014,73839,609Nov 19 05:47 PM
Silva Paul MSVP & Corp ControllerNov 15Sale163.75121,96516,087Nov 19 05:52 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Option Exercise86.522,330201,59241,443Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Option Exercise103.095,803598,21151,002Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Option Exercise86.522,330201,59241,939Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Option Exercise86.521,941167,93548,603Nov 06 04:45 PM
Sachdev AmitEVP, CRONov 05Sale173.731,941337,20446,662Nov 06 04:45 PM
Parini MichaelEVP, CL&AONov 05Sale172.082,330400,94639,609Nov 06 04:32 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Sale172.085,803998,58046,752Nov 06 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Sale172.082,330400,94639,113Nov 06 04:11 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Option Exercise91.051,796163,52640,909Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Option Exercise91.052,155196,21348,817Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Option Exercise91.052,155196,21348,907Nov 05 04:52 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Sale175.362,155377,90146,752Nov 05 04:52 PM
Sachdev AmitEVP, CRONov 02Sale172.862,155372,50546,662Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Sale175.361,796314,94739,113Nov 06 04:11 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86641,734Oct 16 04:29 PM
Parini MichaelEVP, CL&AOOct 12Sale177.202,125376,55039,609Oct 16 04:29 PM
Kewalramani ReshmaEVP and CMOOct 08Sale186.952,305430,9201,909Oct 09 04:50 PM
Parini MichaelEVP, CL&AOOct 04Option Exercise122.454,250520,41343,859Oct 05 05:35 PM
Parini MichaelEVP, CL&AOOct 04Sale191.584,250814,21539,609Oct 05 05:35 PM
Bhatia Sangeeta N.DirectorOct 03Option Exercise126.386,818861,6509,579Oct 05 05:28 PM
Bhatia Sangeeta N.DirectorOct 03Sale192.136,8181,309,9424,879Oct 05 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Option Exercise155.572,445380,36941,558Oct 02 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Sale194.622,445475,84639,113Oct 02 04:30 PM
Graney ThomasChief Financial OfficerOct 01Sale193.241,076207,92612,430Oct 02 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Option Exercise131.892,125280,26641,238Aug 30 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Sale181.892,125386,51639,113Aug 30 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise103.095,803598,21152,555Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Option Exercise86.5280969,99516,896Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59241,443Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Option Exercise86.521,942168,02248,604Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59241,939Aug 07 04:46 PM
Parini MichaelEVP, CL&AOAug 03Sale174.202,330405,88639,609Aug 07 04:46 PM
Sachdev AmitEVP, CROAug 03Sale175.101,942340,05046,662Aug 06 06:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale174.202,330405,88639,113Aug 06 05:42 PM
Silva Paul MSVP & Corp ControllerAug 03Sale174.20809140,92816,087Aug 06 05:38 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale174.205,8031,010,88346,752Aug 06 05:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise111.334,280476,47948,907Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,376Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Option Exercise91.051,796163,52640,909Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Option Exercise91.052,155196,21348,817Aug 06 06:19 PM
Sachdev AmitEVP, CROAug 02Sale176.732,155380,85246,662Aug 06 06:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Sale174.591,796313,56439,113Aug 06 05:42 PM
Silva Paul MSVP & Corp ControllerAug 02Sale174.591,289225,04716,087Aug 06 05:38 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale176.784,280756,61646,752Aug 06 05:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Option Exercise131.8923,3753,082,92962,488Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Option Exercise96.8786083,30816,947Jul 18 05:44 PM
Silva Paul MSVP & Corp ControllerJul 16Sale179.85860154,67116,087Jul 18 05:44 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Sale182.0023,3754,254,25039,113Jul 18 05:32 PM
Sachdev AmitEVP, CROJul 16Sale180.361,719310,04246,662Jul 17 06:30 PM
LB L Brands, Inc. daily Stock Chart
LB [NYSE]
L Brands, Inc.
IndexS&P 500 P/E11.54 EPS (ttm)2.31 Insider Own0.10% Shs Outstand271.50M Perf Week0.34%
Market Cap7.24B Forward P/E10.50 EPS next Y2.54 Insider Trans-0.51% Shs Float227.40M Perf Month-0.34%
Income644.10M PEG2.18 EPS next Q0.00 Inst Own75.50% Short Float5.37% Perf Quarter-2.06%
Sales13.24B P/S0.55 EPS this Y-21.90% Inst Trans-1.16% Short Ratio2.74 Perf Half Y-10.14%
Book/sh-4.78 P/B- EPS next Y6.37% ROA11.40% Target Price30.50 Perf Year-32.34%
Cash/sh1.28 P/C20.81 EPS next 5Y5.30% ROE-86.20% 52W Range23.71 - 39.23 Perf YTD3.90%
Dividend1.20 P/FCF181.02 EPS past 5Y4.20% ROI25.90% 52W High-32.02% Beta0.53
Dividend %4.50% Quick Ratio0.50 Sales past 5Y3.80% Gross Margin37.00% 52W Low12.48% ATR0.97
Employees25200 Current Ratio1.40 Sales Q/Q6.00% Oper. Margin12.10% RSI (14)47.34 Volatility3.48% 3.54%
OptionableYes Debt/Eq- EPS Q/Q-151.80% Profit Margin6.80% Rel Volume0.85 Prev Close27.89
ShortableYes LT Debt/Eq- EarningsFeb 27 AMC Payout75.10% Avg Volume4.45M Price26.67
Recom2.80 SMA20-1.08% SMA50-1.61% SMA200-12.62% Volume3,783,666 Change-4.37%
Mar-01-19Upgrade Barclays Equal Weight → Overweight $31
Mar-01-19Reiterated Telsey Advisory Group Market Perform $31 → $28
Mar-01-19Downgrade Bernstein Outperform → Mkt Perform $30
Jan-11-19Reiterated Telsey Advisory Group Market Perform $33 → $31
Nov-21-18Reiterated Telsey Advisory Group Market Perform $40 → $33
Nov-12-18Upgrade Wells Fargo Market Perform → Outperform
Nov-08-18Upgrade KeyBanc Capital Mkts Underweight → Sector Weight
Oct-26-18Initiated Goldman Buy $36
Sep-18-18Upgrade BofA/Merrill Underperform → Neutral
Aug-24-18Reiterated Telsey Advisory Group Market Perform $36 → $31
Aug-24-18Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-23-18Reiterated B. Riley FBR Buy $49 → $44
Aug-10-18Initiated Wedbush Neutral $33
May-14-18Upgrade Citigroup Neutral → Buy
May-10-18Downgrade Loop Capital Hold → Sell
Apr-13-18Reiterated Telsey Advisory Group Market Perform $52 → $41
Mar-13-18Initiated Credit Suisse Neutral $45
Mar-09-18Initiated Loop Capital Hold $45
Mar-01-18Downgrade Telsey Advisory Group Outperform → Market Perform $70 → $52
Feb-12-18Reiterated Wolfe Research Peer Perform $48 → $53
Mar-22-19 06:48PM  L Brands Inc (LB) Files 10-K for the Fiscal Year Ended on January 31, 2019 GuruFocus.com
Mar-20-19 06:00AM  Bear of the Day: Urban Outfitters, Inc. (URBN) Zacks
Mar-19-19 12:12PM  Stocks - Dow Downed as Trade Talks Sour Investing.com
Mar-18-19 02:17PM  Bathing suits are back at Victoria's Secret CNBC
12:13PM  Victoria's Secret Announces Return of Swim Online PR Newswire
Mar-07-19 04:56PM  Jean Chatzky on money lessons to teach children Yahoo Finance Video
11:32AM  2019's biggest winners were 2018's biggest losers Yahoo Finance
11:27AM  Payless, other retail closures may be fortuitous for local real estate American City Business Journals
Mar-06-19 09:00PM  How The 3 Weeks Tight Pattern Gives You An Extra Buy Point Investor's Business Daily
06:14PM  Edited Transcript of LB earnings conference call or presentation 28-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
11:42AM  Abercrombie & Fitch CEO has no plans to break up the company Yahoo Finance
11:33AM  Where Ohio billionaires rank on Forbes list of the richest people in the world American City Business Journals
10:54AM  12 Dividend Stocks That May Be Income Traps Kiplinger
10:13AM  US STOCKS-Wall St flat, investors await fresh update on trade Reuters
Mar-05-19 02:53PM  Activist investor calls for L Brands to split up Victoria's Secret, Bath & Body Works American City Business Journals
01:51PM  L Brands says it's already focused on merchandise, costs in response to shareholder Barington MarketWatch
01:40PM  Barington Capital Wants L Brands to Spin Off Victoria's Secret Brand TheStreet.com
01:34PM  Investor pushes L Brands to spin off Victoria's Secret Reuters
01:15PM  L Brands Issues Statement in Response to Barington Capital GlobeNewswire
01:03PM  L Brands Should Split Up, Activist Says. Will What Worked for Gap Work for Its Stock? Barrons.com
11:58AM  Stocks drift between small gains, losses in midday trading Associated Press
11:29AM  Heavy trading in L Brands on push for sale, spin-off Associated Press
09:07AM  Investor asks L Brands to separate Victoria's Secret, Bath & Body Works CNBC
08:39AM  Investor pushes L Brands to spin off Victoria's Secret Reuters
08:07AM  What Amazon Will Do in Groceries and 2 More Things to Know About Stocks for Tuesday Barrons.com
07:49AM  Stocks making the biggest moves premarket: Target, Kohl's, Papa John's & more CNBC
07:29AM  Barington urges Victoria's Secret parent to consider a spin-off or an IPO of Bath & Body Works MarketWatch
07:16AM  Investor Barington pushes L Brands for Victoria's Secret spinoff Reuters
12:24AM  [$$] L Brands Faces Pressure to Separate Victorias Secret, Bath & Body Works The Wall Street Journal
Mar-04-19 08:44PM  [$$] Activist investor urges Victorias Secret owner to overhaul business Financial Times
02:10PM  Here's how tax refunds are impacting retailers CNBC Videos
08:46AM  L Brands (LB) Catches Eye: Stock Jumps 5.2% Zacks
08:44AM  Did Changing Sentiment Drive L Brandss Share Price Down A Worrying 69%? Simply Wall St.
Mar-03-19 11:04AM  Bulls & Bears Of The Week: Apple, Tesla, Home Depot, Walgreens And More Benzinga
Mar-02-19 01:37PM  Barron's Picks And Pans: Conagra, JPMorgan, L Brands, Weight Watchers And More Benzinga
Mar-01-19 09:15PM  Why L Brands Stock Is Still Not a Buy Barrons.com +5.20%
03:41PM  5 Retail Stocks Ready to Break Out InvestorPlace
01:21PM  More Than 50 Victorias Secret Stores Closing in 2019 InvestorPlace
12:14PM  Stocks making the biggest moves midday: Gap, Tesla, L Brands & more CNBC
09:30AM  Company News For Mar 1, 2019 Zacks
08:22AM  Some retailers are starting to feel the pinch from delayed tax refunds Yahoo Finance
08:04AM  Tesla Reveals a $35,000 Car, L Brands Covers Up, and More to Know About Stocks for Friday Barrons.com
06:46AM  Here are the biggest analyst calls of the day: Delta, American Airlines, L Brands, Hertz, Party City & Michaels CNBC
06:35AM  Victoria's Secret Owner L Brands Suddenly Turning Heads Midday Investing.com
Feb-28-19 08:09PM  L Brands Inc (LB) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:32PM  [$$] Holiday Sales Havent Rescued J.C. Penney, Victorias Secret The Wall Street Journal
01:04PM  [$$] Holiday Sales Haven't Rescued J.C. Penney, Victoria's Secret The Wall Street Journal
12:38PM  L Brands Stock Is Tumbling Because Earnings Show the Worst Isnt Over Yet Barrons.com
11:38AM  Victoria's Secret talks store closings, increased competition American City Business Journals
10:28AM  L Brands Could Be A Turnaround Story In 2019, Says Bullish Wells Fargo Benzinga
09:10AM  [$$] Stocks to Watch: Square, J.C. Penney, L Brands, HP, Box, Fitbit, Monster Beverage The Wall Street Journal
08:57AM  Victoria's Secret will continue to lose market share to American Eagle's Aerie: UBS MarketWatch
08:46AM  Implied Volatility Surging for L Brands (LB) Stock Options Zacks
08:34AM  L Brands Falls After Earnings Miss, Weak Guidance TheStreet.com
07:58AM  Stocks making the biggest moves premarket: JC Penney, Square, Tesla, L Brands & more CNBC
07:45AM  L Brands to close 53 Victoria's Secret stores, says 'everything is on the table' for lingerie brand CNBC
07:34AM  L Brands (LB) Down More Than 6% Despite Q4 Earnings Beat Zacks
02:37AM  L Brands issues weak Victoria's Secret sales; fiscal-year forecast below estimates Reuters
02:34AM  L Brands issues weak Victoria's Secret sales; FY forecast below estimates Reuters
01:46AM  Stocks - U.S. Futures Drop as North Korea Talks Collapse; 4Q GDP Ahead Investing.com
Feb-27-19 06:12PM  L Brands Earnings: LB Stock Slumps as Victorias Secret Comps Dip InvestorPlace
06:10PM  Retail is racking up big gains this week and these names in the space are headed even higher CNBC Videos
05:40PM  Stocks making the biggest moves after hours: L Brands, Square, HP and more CNBC
04:55PM  [$$] L Brands Reports Decline in Victoria Secret Sales The Wall Street Journal
04:37PM  Shares of Victoria's Secret-owner L Brands plunge on weak forecast, mixed holiday results CNBC
04:35PM  Victoria's Secret parent stock falls 8% after mixed Q4 results MarketWatch
04:15PM  L Brands Reports Fourth Quarter and Full-Year 2018 Earnings GlobeNewswire
01:11PM  L Brands Earnings beat, Revenue misses In Q4 Investing.com
10:59AM  Top 2 Companies Owned by L Brands, Including Victoria's Secret (Lb) Investopedia
05:46AM  [$$] L Brands outlook misses forecasts as Victorias Secret sales shrink Financial Times
Feb-26-19 11:14AM  How did L Brands (and other local retailers) fare with customers in 2018? American City Business Journals
Feb-25-19 04:43PM  Target takes on Victoria's Secret with new sleepwear and lingerie Yahoo Finance Video
03:45PM  General Electric makes major sale, Roche buys Spark Therapeutics, Target takes on Victorias Secrets Yahoo Finance
02:14PM  Why Retail Stocks Are The New Big Short Investopedia
11:22AM  Victoria's Secret Should Be Terrified of Target Motley Fool
10:01AM  Target's latest in-store brands: A trio of intimate labels American City Business Journals
09:03AM  Target debuts three lingerie and sleepwear lines American City Business Journals
Feb-24-19 08:38PM  [$$] Target Takes on Victorias Secret The Wall Street Journal
09:02AM  [$$] Target Takes on Victoria's Secret The Wall Street Journal
01:08AM  Economic Calendar - Top 5 Things to Watch This Week Investing.com
Feb-22-19 02:08PM  Equifax adds L Brands data scientist to its reshaped board of directors American City Business Journals
09:37AM  Check Out L Brands' (LB) Probability to Beat in Q4 Earnings Zacks
08:30AM  Equifax names Heather H. Wilson as new independent director PR Newswire
Feb-20-19 10:35AM  L Brands, Inc. : L Brands Invites You To Listen To Its Fourth Quarter 2018 Earnings Call Webcast GlobeNewswire
10:31AM  Earnings Preview: L Brands (LB) Q4 Earnings Expected to Decline Zacks
Feb-19-19 04:14PM  How the Victoria's Secret Credit Card Works: Benefits and Rewards (LB) Investopedia
Feb-14-19 08:25AM  Market Trends Toward New Normal in L Brands, Tetra Tech, Dril-Quip, DCP Midstream Partners, LP, Carbonite, and Badger Meter Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
05:24AM  8 Stocks That Can Lead in a 'Micro-Driven' Market Investopedia
Feb-13-19 11:23PM  [$$] US key holiday retail sales shrink by most since 2009 Financial Times
09:37AM  Victoria's Secret to feature Parisian lingerie brand LIVY at select stores MarketWatch
08:48AM  Victoria's Secret To Feature Lingerie Label LIVY PR Newswire
Feb-11-19 04:47PM  L Brands (LB) Reports January Sales, Comps Lose Momentum Zacks
Feb-10-19 09:27PM  4 Overlooked Value Stocks Ready to Outperform in 2019 Investopedia
Feb-08-19 09:41PM  Barington Capital Groups Return, AUM and Holdings Insider Monkey
09:27AM  Buckle (BKE) Showcases Soft Comps Performance in January Zacks
Feb-07-19 05:18PM  Victoria's Secret Angels Share The Perfect Gifts For Valentine's Day PR Newswire
07:15AM  L Brands Reports January 2019 Sales GlobeNewswire
Feb-06-19 01:36PM  Final Trades: eBay, Twitter, L Brands, Boston Scientific, & McKesson CNBC Videos
Feb-05-19 07:23AM  Why You Should Like L Brands, Inc.s (NYSE:LB) ROCE Simply Wall St.
Feb-04-19 10:01PM  Youll love having these hated stocks in your portfolio MarketWatch
L Brands, Inc. operates as a specialty retailer of women's intimate and other apparel, beauty and personal care products, home fragrance products, and accessories. The company operates in three segments: Victoria's Secret, Bath & Body Works, and Victoria's Secret and Bath & Body Works International. Its products include loungewear, bras, panties, athletic attire, shower gels and lotions, aromatherapy, body care, soaps and sanitizers, handbags, jewelry, and personal care accessories. The company offers its products under the Victoria's Secret, PINK, Bath & Body Works, La Senza, Henri Bendel, C.O. Bigelow, White Barn, and other brand names. L Brands, Inc. sells its merchandise through company-owned specialty retail stores, which are primarily mall-based; through its Websites comprising VictoriasSecret.com, BathandBodyWorks.com, HenriBendel.com, and LaSenza.com; and through franchises, licenses, and wholesale partners. As of September 13, 2018, the company operated 3,084 company-owned specialty stores in the United States, Canada, the United Kingdom, Ireland, and Greater China, as well as sold its brands through approximately 800 franchised locations and online worldwide. The company was formerly known as Limited Brands, Inc. and changed its name to L Brands, Inc. in March 2013. L Brands, Inc. was founded in 1963 and is headquartered in Columbus, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZIMMERMAN RAYMONDDirectorNov 21Sale28.336,385180,87737,693Nov 26 06:17 PM
Bersani James L.EVP & President - Real EstateJul 06Buy36.285,000181,400219,893Nov 26 06:17 PM
JAMES DONNADirectorMay 25Sale35.291,00035,29219,738May 30 10:39 AM
GPRO GoPro, Inc. daily Stock Chart
GPRO [NASD]
GoPro, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own0.30% Shs Outstand147.36M Perf Week2.88%
Market Cap949.00M Forward P/E20.64 EPS next Y0.31 Insider Trans-76.34% Shs Float113.68M Perf Month6.10%
Income-109.00M PEG- EPS next Q-0.09 Inst Own54.60% Short Float33.13% Perf Quarter40.31%
Sales1.15B P/S0.83 EPS this Y0.00% Inst Trans3.79% Short Ratio9.53 Perf Half Y1.74%
Book/sh1.51 P/B4.26 EPS next Y8.71% ROA-16.40% Target Price6.25 Perf Year30.89%
Cash/sh1.34 P/C4.81 EPS next 5Y10.00% ROE-55.40% 52W Range4.00 - 7.60 Perf YTD51.89%
Dividend- P/FCF- EPS past 5Y-33.20% ROI-27.10% 52W High-15.26% Beta0.73
Dividend %- Quick Ratio1.20 Sales past 5Y3.10% Gross Margin31.60% 52W Low61.00% ATR0.22
Employees891 Current Ratio1.60 Sales Q/Q12.70% Oper. Margin-8.20% RSI (14)65.55 Volatility3.24% 3.64%
OptionableYes Debt/Eq0.66 EPS Q/Q61.10% Profit Margin-9.50% Rel Volume0.67 Prev Close6.53
ShortableYes LT Debt/Eq0.66 EarningsFeb 06 AMC Payout- Avg Volume3.95M Price6.44
Recom2.80 SMA204.26% SMA5015.19% SMA2009.37% Volume2,665,022 Change-1.38%
Sep-26-18Upgrade Oppenheimer Perform → Outperform
Feb-05-18Reiterated Citigroup Neutral $7 → $5.50
Feb-02-18Downgrade JP Morgan Overweight → Neutral $8
Jan-23-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-09-18Reiterated Wedbush Neutral $10.50 → $6
Jan-09-18Reiterated Dougherty & Company Sell $7 → $4
Jan-08-18Downgrade Longbow Buy → Neutral
Oct-18-17Upgrade Longbow Neutral → Buy
Oct-02-17Reiterated Dougherty & Company Sell $5 → $7
Aug-15-17Upgrade Goldman Sell → Neutral
Aug-04-17Upgrade Raymond James Underperform → Mkt Perform
Aug-04-17Upgrade Longbow Underperform → Neutral
Jul-31-17Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-17Upgrade Citigroup Sell → Neutral
Mar-16-17Reiterated Stifel Hold $10 → $9
Mar-06-17Downgrade Goldman Neutral → Sell
Mar-03-17Initiated Citigroup Sell $8
Feb-03-17Reiterated Dougherty & Company Sell $6 → $5
Feb-03-17Downgrade Robert W. Baird Neutral → Underperform $10 → $6
Feb-03-17Downgrade Raymond James Mkt Perform → Underperform
Mar-19-19 05:05PM  China's GoPro rival plans IPO in 2020 after raising fresh round of funding CNBC
05:00PM  Chinese GoPro Competitor Insta360 Targets an IPO by 2020 Bloomberg
Mar-15-19 03:33PM  The 5 Best Stocks to Invest in Self-Driving Cars InvestorPlace
Mar-13-19 10:04AM  There Isnt a Lot of Hope Left for People Investing in GoPro Stock InvestorPlace
Mar-11-19 06:00AM  GPRO Stock Suffers a Relevancy Problem InvestorPlace
Mar-10-19 01:38PM  Ambarella Is Poised for a Comeback as Next-Gen Camera Chipmaker for Cars TheStreet.com
01:00PM  Reasons to Buy Fitbit Stock If It Dips InvestorPlace
Mar-09-19 09:02AM  We went skiing with GoPro CEO Nick Woodman to hear his story of the company's turbulent past and why he thinks things are looking up CNBC Videos
09:01AM  GoPro CEO Nick Woodman opens up on the company's wild ride of failures and successes CNBC
Mar-08-19 09:30AM  Why Is GoPro (GPRO) Up 15% Since Last Earnings Report? Zacks
Mar-04-19 09:15PM  Gopro Inc (GPRO) CEO, Chairman of the Board Nicholas Woodman Sold $8.3 million of Shares GuruFocus.com
Mar-01-19 09:15AM  Stocks Rise Over 3% in February Zacks
Feb-28-19 05:42PM  Uber and Lyft and others will dole out IPO shares to non-employees. Here are other companies that have done it American City Business Journals -6.42%
09:00AM  GoPro HERO7 Black Goes White-Hot! PR Newswire
Feb-23-19 03:00PM  3 Risks Facing Ambarella Stock Motley Fool
Feb-21-19 03:23PM  Roku Stock Is a Long-Term Winner Sprinting Into Earnings InvestorPlace
Feb-20-19 09:30AM  SNE or GPRO: Which Is the Better Value Stock Right Now? Zacks
07:50AM  New Research Coverage Highlights GoPro, McCormick & Company, CenterPoint Energy, ViewRay, Hudson Pacific Properties, and Sterling Construction Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-15-19 07:30AM  The typical Facebook employee earns double Silicon Valley's median household income. How 50+ big tech employers compare American City Business Journals
Feb-14-19 05:01AM  Why Buying Sonos After the Dip Is Not a Leap of Faith By Any Measure InvestorPlace
Feb-12-19 10:16AM  After GoPros Surprise Profit, Should Investors Buy GoPro Stock? InvestorPlace
09:25AM  3 Reasons to Sell Fitbit Stock Ahead of This Months Earnings InvestorPlace
Feb-11-19 10:25AM  GoPro Finally Has a Good Christmas Quarter InvestorPlace
Feb-08-19 02:35PM  GoPro predicts profit, thanks to years of massive layoffs MarketWatch
10:59AM  Sonos Stock Still Isnt Cheap Enough to Buy InvestorPlace
Feb-07-19 04:25PM  Twitter says that it has 60 million less daily active users than Snap Fox Business Videos
04:10PM  Analysts See Blurry Longterm Picture For GoPro Despite Profitable Quarter Benzinga
03:50PM  GoPro Ends 2018 on a Strong Note Motley Fool
03:32PM  Edited Transcript of GPRO earnings conference call or presentation 6-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
12:45PM  GoPro CEO Says Moving Production to Mexico 'Makes Sense' Bloomberg
12:04PM  GoPro CEO Still Sees Growth in China, Despite Economic Slowdown Bloomberg
10:50AM  GoPro (GPRO) Q4 Earnings Top Estimates on Revenue Growth Zacks
08:56AM  Hain Stock Slumps, GoPro Jumps and 5 More Thursday Morning Movers Barrons.com
Feb-06-19 08:12PM  GoPro Inc (GPRO) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:20PM  GoPro (GPRO) Q4 Earnings and Revenues Beat Estimates Zacks
05:58PM  GoPro tops revenue estimates, posts first profit in five quarters Reuters
05:40PM  GoPro Earnings: GPRO Stock Edges Higher on Strong Q4 EPS, Sales InvestorPlace
05:26PM  GoPro: 4Q Earnings Snapshot Associated Press
04:17PM  GoPro tops revenue estimates, posts first profit in five quarters Reuters
04:15PM  GoPro stock gains after earnings top expectations MarketWatch
04:05PM  GoPro Announces Fourth Quarter and Full Year 2018 Results PR Newswire
03:00PM  GoPro, Inc. Class A to Host Earnings Call ACCESSWIRE
01:23PM  What GoPro Stock Holders Need to Know Before Earnings InvestorPlace
12:31PM  Stocks Moving After Hours: Chipotle, Match, GoPro, Costco Investing.com
11:31AM  Spotify moves beyond music, and GoPro also aims to change its tune MarketWatch
Feb-04-19 01:01PM  8 Companies That Could Disappear Before 2019 Is Over InvestorPlace
09:50AM  Will Revenue Growth Support GoPro's (GPRO) Q4 Earnings? Zacks
09:30AM  SNE vs. GPRO: Which Stock Is the Better Value Option? Zacks
Jan-30-19 10:31AM  GoPro (GPRO) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:00AM  The Sky's The Limit, but the Price Remains the Same: GoPro Adds Unlimited Cloud Storage of Original Quality Videos and Photos to $4.99 Plus Subscription Service PR Newswire
09:00AM  GoPro Plus now offers unlimited uncompressed video storage Engadget
Jan-28-19 09:33AM  Contentsquare collects $60 million from Eurazeo American City Business Journals
08:44AM  Do Options Traders Know Something About GoPro (GPRO) Stock We Don't? Zacks
Jan-17-19 09:30AM  SNE vs. GPRO: Which Stock Is the Better Value Option? Zacks
Jan-16-19 04:44PM  GoPro improves Fusion VR camera resolution via software update Engadget
04:05PM  GoPro Schedules Fourth Quarter and Full Year 2018 Financial Results for February 6, 2019 PR Newswire
Jan-14-19 07:48AM  GoPro CEO: There was no boogeyman this holiday quarter MarketWatch
Jan-11-19 11:15AM  At This Point Only a Buyout Can Save Ailing GoPro Stock InvestorPlace
Jan-10-19 10:00AM  GoPro's Nick Woodman is happy he gave away a million dollars Engadget
Jan-09-19 09:15PM  Is GoPro Set for Success in 2019? Motley Fool
03:50PM  GoPro CEO: Tariff concerns were catalyst for moving production out of China Fox Business Videos
Jan-08-19 09:15AM  Portfolios Making Up For Lost Time Zacks
Jan-07-19 01:07PM  Here's what a promising startup and 30 Bay Area honorees are showing off at CES this week American City Business Journals
09:00AM  Believe the Hype: GoPro Showcases Award-Winning HERO7 Cameras at CES 2019 PR Newswire
Dec-27-18 08:48AM  Do Options Traders Know Something About GoPro (GPRO) Stock We Don't? Zacks
Dec-24-18 07:29AM  GoPro's (GPRO) HERO7 Black Gains Prominence in Industry Zacks
Dec-22-18 04:20AM  Is GoPro Inc (GPRO) A Good Stock To Buy? Insider Monkey
Dec-21-18 09:00AM  GoPro HERO7 Black Honored For Breakthrough Innovations PR Newswire
Dec-20-18 09:02AM  Will AR & VR Technologies Live Up to Expectations in 2019? Zacks -6.75%
Dec-17-18 11:27AM  Stocks pare losses Yahoo Finance
09:14AM  GoPro's (GPRO) HERO7 Black Customers Win Award of $1 Million Zacks
Dec-15-18 07:49AM  GoPro founder reveals what's next for the action camera maker Yahoo Finance
07:30AM  GoPro Wants Fusion to Be the Next Action Camera Motley Fool
Dec-14-18 12:39PM  GoPro CEO speaks about the tech companys future Yahoo Finance Video
10:50AM  GoPro CEO speaks out on companys future Yahoo Finance Video
09:07AM  GoPro Awards $1 Million Dollars to HERO7 Black Customers for Crowd-Sourced Highlight Video PR Newswire
Dec-12-18 05:38PM  Apple Reportedly Weighing Move Away from Manufacturing in China Due to Tariffs TheStreet.com
Dec-11-18 06:19PM  GoPro Betting on Discounts for the Holidays Motley Fool
05:56PM  GoPro to Move Most of U.S.-Bound Camera Production Out of China Zacks
01:03PM  GoPro, Inc. (NASDAQ:GPRO): Time For A Financial Health Check Simply Wall St.
10:18AM  More companies getting out of China amid trade war Yahoo Finance Video
09:16AM  Trump's trade war with China is causing CEOs to make one risky change Yahoo Finance
Dec-10-18 09:49PM  GoPro will move production of most US-bound cameras out of China by next summer TechCrunch
02:34PM  GoPro Takes the Lead in Shift Out of China to Avoid Tariffs Bloomberg
12:33PM  GoPro will make 'most' of its US cameras outside of China Engadget
11:57AM  GoPro to move production out of China over tariff concerns Associated Press
11:55AM  GoPro to Move U.S.-Bound Camera Production Out of China TheStreet.com
11:43AM  GoPro to move production out of China over tariff concerns Associated Press
10:39AM  GoPro to move U.S.-bound camera production out of China Reuters
10:23AM  GoPro moves U.S.-bound action cam production from China due to tariffs American City Business Journals
09:58AM  GoPro to move U.S.-bound camera production out of China Reuters
09:44AM  Action camera maker GoPro to move production of U.S.-bound cameras out of China over tariffs MarketWatch
09:19AM  GoPro is moving camera production out of China over tariff concerns CNBC
09:18AM  GoPro plans to move U.S.-bound camera production out of China Reuters
09:15AM  GoPro to Move U.S.-Bound Camera Production From China on Tariff Bloomberg
09:00AM  GoPro Plans To Move US-Bound Camera Production Out Of China PR Newswire
Dec-09-18 09:55PM  [$$] GoPro shifts production out of China to avoid tariff threat Financial Times
09:14AM  Is GoPro a Buy? Motley Fool
Dec-05-18 07:51AM  GoPro Witnesses Solid Sell-Through of HERO7 Lineup Cameras Zacks
Dec-04-18 04:45PM  GoPro Has Strong Black Friday And Cyber Monday PR Newswire
GoPro, Inc. develops and sells cameras, drones, and mountable and wearable accessories in the United States and internationally. The company offers HERO7, a cloud-connected line of camera; Fusion, a waterproof spherical camera; GoPro Plus, a cloud-based storage solution that enables subscribers to access, edit, and share content; Quik, a mobile editing app, as well as desktop app for editing options for power users; GoPro App, a mobile app that allows users to preview and play back photos and videos, control GoPro cameras, and share content; and Karma Grip, a handheld or body-mountable camera stabilizer that capture zero-shake smooth video. It also offers mounts and accessories comprising equipment-based mounts consisting of helmet, handlebar, roll bar, and tripod mounts that enable consumers to wear the mount on their bodies, such as wrist housings, chest harnesses, and head straps. GoPro, Inc. markets and sells its products through retailers and wholesale distributors, as well as through its Website. The company was formerly known as Woodman Labs, Inc. and changed its name to GoPro, Inc. in February 2014. GoPro, Inc. was founded in 2004 and is headquartered in San Mateo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woodman NicholasCEO, Chairman of the BoardMar 01Sale6.04660,0513,987,0380Mar 04 07:31 PM
Woodman NicholasCEO, Chairman of the BoardFeb 28Sale5.85739,9494,325,8900Mar 04 07:31 PM
MCGEE BRIANEVP, Chief Financial OfficerFeb 20Sale6.0419,526117,96468,262Feb 20 05:30 PM
Ahmad-Taylor TyroneDirectorNov 19Sale5.444,18822,79012,567Nov 19 04:59 PM
MCGEE BRIANEVP, Chief Financial OfficerNov 16Sale5.362,45313,14899,209Nov 19 02:41 PM
MCGEE BRIANEVP, Chief Financial OfficerAug 16Sale5.865,45231,949102,959Aug 17 04:51 PM
RDY Dr. Reddy's Laboratories Limited daily Stock Chart
RDY [NYSE]
Dr. Reddy's Laboratories Limited
Index- P/E25.30 EPS (ttm)1.55 Insider Own27.70% Shs Outstand162.90M Perf Week0.75%
Market Cap6.38B Forward P/E22.82 EPS next Y1.72 Insider Trans0.00% Shs Float149.41M Perf Month8.78%
Income257.30M PEG1.99 EPS next Q- Inst Own13.50% Short Float0.98% Perf Quarter6.91%
Sales2.15B P/S2.97 EPS this Y-7.30% Inst Trans6.57% Short Ratio6.74 Perf Half Y8.18%
Book/sh11.80 P/B3.32 EPS next Y34.27% ROA7.60% Target Price28.03 Perf Year18.06%
Cash/sh2.19 P/C17.85 EPS next 5Y12.70% ROE13.30% 52W Range28.13 - 40.84 Perf YTD3.87%
Dividend0.29 P/FCF20.99 EPS past 5Y-7.40% ROI4.90% 52W High-4.11% Beta0.09
Dividend %0.74% Quick Ratio1.30 Sales past 5Y4.10% Gross Margin54.50% 52W Low39.21% ATR0.79
Employees23524 Current Ratio1.80 Sales Q/Q1.20% Oper. Margin12.20% RSI (14)55.82 Volatility1.78% 1.69%
OptionableYes Debt/Eq0.32 EPS Q/Q13.50% Profit Margin11.70% Rel Volume1.18 Prev Close40.31
ShortableYes LT Debt/Eq0.18 EarningsFeb 01 BMO Payout- Avg Volume217.18K Price39.16
Recom- SMA202.27% SMA503.49% SMA20011.62% Volume255,269 Change-2.85%
Feb-19-19Upgrade CLSA Outperform → Buy
Jan-17-19Downgrade Citigroup Neutral → Sell
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-31-17Upgrade CLSA Underperform → Outperform
Jul-28-17Downgrade CLSA Underperform → Sell
Jul-27-16Downgrade Jefferies Hold → Underperform
Jul-27-16Downgrade HSBC Securities Hold → Reduce
Feb-10-16Upgrade Credit Agricole Underperform → Buy
Nov-10-15Downgrade Citigroup Buy → Neutral
Jan-21-11Initiated HSBC Securities Overweight
Jan-19-10Downgrade Deutsche Bank Hold → Sell
Oct-26-09Upgrade Credit Suisse Neutral → Outperform
Jun-10-09Upgrade Citigroup Hold → Buy
Mar-07-08Downgrade Citigroup Buy → Hold
Jun-13-07Upgrade Credit Suisse Neutral → Outperform
May-21-07Upgrade JP Morgan Underweight → Neutral
Mar-20-19 10:38AM  Top Ranked Momentum Stocks to Buy for March 20th Zacks
Mar-01-19 07:20AM  Factors of Influence in 2019, Key Indicators and Opportunity within Vanda Pharmaceuticals, Range Resources, Fortune Brands Home & Security, Dr. Reddy's Laboratories, BWX Technologies, and K12 New Research Emphasizes Economic Growth GlobeNewswire
Feb-27-19 06:16PM  Watching for Signs of Global Risk Events Investopedia
Feb-20-19 12:01PM  Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation Business Wire
Feb-12-19 03:00AM  Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market Business Wire
Feb-04-19 03:41PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3 Zacks
12:51AM  Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling Business Wire
Feb-01-19 10:17AM  Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America Business Wire
09:27AM  Dr. Reddy's (RDY) Earnings Rise in Q3, Sales Increase Y/Y Zacks
07:45AM  Dr. Reddys Q3 FY19 Financial Results Business Wire
04:59AM  Dr. Reddy's third-quarter profit surges on strong growth in emerging markets Reuters
Jan-28-19 05:55PM  Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store? Zacks
Jan-27-19 11:53PM  Dr. Reddy's Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market Business Wire
Jan-24-19 03:25AM  Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market Business Wire
Jan-11-19 04:57AM  Dr. Reddy's to Release Q3 FY19 Results on February 1, 2019 Business Wire
Jan-10-19 02:54PM  Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility Zacks
10:05AM  Top-Ranked Sector ETFs & Stocks to Buy for 2019 Zacks
Jan-07-19 08:17AM  Dr. Reddy's Laboratories Limited to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-03-19 03:29PM  VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster Zacks
03:03PM  Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar Zacks
Dec-31-18 08:04AM  The Zacks Analyst Blog Highlights: Internet Initiative Japan, Sony, Ingersoll-Rand, HDFC Bank and Dr. Reddy's Laboratories Zacks
Dec-28-18 09:55AM  Generic Industry on Path to Recovery: 3 Hot Picks for 2019 Zacks
09:05AM  5 ADRs That More Than Doubled the S&P 500 in 2018 Zacks
Dec-27-18 07:22AM  Highlighted as Zacks Bull and Bear of the Day Dr. Reddy???s Laboratories, Dillard???s, Facebook, Netflix and Amazon Zacks
02:03AM  Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market Business Wire
Dec-24-18 01:30AM  Dr. Reddy's Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market Business Wire
Dec-19-18 07:05AM  Today's Research Reports on Trending Tickers: Dr. Reddy's Laboratories and AbbVie ACCESSWIRE
Dec-18-18 10:30AM  Zacks.com featured highlights include: Abercrombie, Dr. Reddy???s, Cree, Otter and Shenandoah Zacks
Dec-14-18 08:11AM  Bet on These 5 Low-Beta Stocks to Fight Market Volatility Zacks
Dec-13-18 11:14AM  Should Warren Buffett And You Buy More TEVA Stock Right Now? InvestorPlace
Dec-11-18 09:23AM  Generic Drugmakers Down on Allegations of Price Fixing Zacks
06:57AM  Generic-drug stocks slammed by report of expanded price-fixing probe MarketWatch
12:43AM  Dr. Reddys announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market Business Wire
Dec-10-18 11:30AM  Generic drug makers stocks fall sharply after report of expanded price-fixing probe MarketWatch
07:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within OSI, BorgWarner, Cubic, Dr. Reddy's Laboratories, Teck Resources, and Gardner Denver New Research Emphasizes Economic Growth GlobeNewswire
Dec-07-18 09:01AM  These 5 stocks are surprising winners amid the markets wild swings MarketWatch
Dec-04-18 09:03AM  The Zacks Analyst Blog Highlights: Anthem, HCA, Dr. Reddy's and UnitedHealth Zacks
Dec-03-18 09:35AM  Healthcare Takes Wall Street Lead: 4 Picks Zacks
Nov-30-18 09:20AM  Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines Zacks
09:15AM  Lilly (LLY) Hits Fresh High: Is There Still Room to Run? Zacks
Nov-29-18 09:41AM  5 Low-Beta Stocks to Weather Market Volatility Zacks
Nov-28-18 03:20AM  Dr. Reddy's Laboratories Announces the Launch of Chlorthalidone Tablets, USP in the U.S. Market Business Wire
Nov-21-18 12:15AM  Dr. Reddy's shares spike after favourable generic drug ruling Reuters
Nov-20-18 08:40PM  Dr. Reddy's Laboratories Announces Favorable Outcome in Buprenorphine and Naloxone Sublingual Film Patent Litigation Business Wire
Nov-19-18 08:57AM  J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment Zacks
Nov-01-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Dr. Reddy's Laboratories, Union Pacific, Zimmer Biomet, Varian Medical, Sonic Automotive, and Axalta Coating Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-31-18 03:51AM  Dr. Reddy's Laboratories Announces the Launch of Atomoxetine Capsules, USP in the U.S. Market Business Wire +5.16%
Oct-29-18 01:44PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2 Zacks
Oct-26-18 09:29AM  Doctor Reddy's: Fiscal 2Q Earnings Snapshot Associated Press
09:22AM  Dr. Reddys Q2 & H1 FY19 Financial Results Business Wire
Oct-16-18 08:00AM  Today's Research Reports on Trending Tickers: Flex Pharma and Dr. Reddy's Laboratories ACCESSWIRE
Oct-15-18 06:12AM  Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market Business Wire
12:48AM  Dr. Reddy's Laboratories Announces the Sale of Its API Manufacturing Business Unit in Jeedimetla, Hyderabad Business Wire
Oct-09-18 09:42AM  IMF Predicts Strong GDP Growth for India: Stocks in Focus Zacks
09:04AM  Dr. Reddy's Laboratories announces the launch of Colesevelam Hydrochloride Tablets in the U.S. Market Business Wire
Oct-03-18 09:42AM  Dr. Reddy's to Release Q2 FY19 Results on October 26, 2018 Business Wire
Oct-02-18 10:16AM  Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker Zacks
04:59AM  Dr. Reddy's Laboratories Announces the Sale of Cloderm® (clocortolone pivalate) Cream, 0.1% Franchise to EPI Health, LLC Business Wire
Oct-01-18 01:45AM  Dr. Reddy's Laboratories Announces the Launch of Imatinib Mesylate Tablets, USP in the U.S. Market Business Wire
01:44AM  Dr. Reddys Laboratories Announces That It Has Regained Worldwide Rights to DFA-02 Business Wire
01:36AM  Dr. Reddy's Laboratories Announces the Sale of Its Antibiotic Manufacturing Site and Its Related Assets in Bristol, Tennessee Business Wire
Sep-19-18 09:32AM  Dr. Reddy's (RDY) Presence in Generics Market Remains Strong Zacks
Sep-12-18 08:31AM  Dr. Reddy's Laboratories Announces the Launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market Business Wire
Aug-10-18 09:11AM  The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Infosys, ICICI Bank and HDFC Bank Zacks
Aug-08-18 09:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. - RDY ACCESSWIRE
Jul-30-18 07:10AM  Initiating Free Research Reports on Synergy Pharma and Three Other Drug Makers Equities ACCESSWIRE
Jul-27-18 09:34AM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1 Zacks
Jul-26-18 04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. - RDY ACCESSWIRE
09:42AM  Doctor Reddy's: Fiscal 1Q Earnings Snapshot Associated Press
08:56AM  Dr. Reddys Q1 FY19 Financial Results Business Wire
06:24AM  Dr.Reddy's profit soars on anti-opioid drug sales in U.S. Reuters
05:40AM  India's Dr. Reddy's Q1 net profit rises seven-fold, beats forecast Reuters
12:46AM  Dr. Reddy's Laboratories Announces the Launch of Hervycta® (trastuzumab biosimilar) in India Business Wire
Jul-23-18 03:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. RDY ACCESSWIRE
Jul-20-18 02:13AM  Dr. Reddys Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market Business Wire
Jul-19-18 07:13PM  Indivior Finance S.ar.l. -- Moody's confirms Indivior's B3 Corporate Family Rating; revises outlook to negative Moody's
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dr. Reddy's Laboratories Limited (RDY) PR Newswire
Jul-18-18 05:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Ltd. RDY GlobeNewswire
Jul-17-18 08:00AM  Today's Research Reports on Stocks to Watch: Dr. Reddy's Laboratories and Intellia Therapeutics ACCESSWIRE
Jul-16-18 03:15PM  Dr.Reddys Laboratories (RDY) Dives Following Court Order InvestorPlace -10.41%
10:58AM  Indivior Soars on Court Ruling Blocking Sales of Rival's Generic Opioid Drug TheStreet.com
Jul-14-18 04:42AM  Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film Business Wire
Jul-11-18 02:51AM  Dr. Reddy's Laboratories Announces the Launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. Market Business Wire
Jul-05-18 09:38AM  Dr. Reddy's to Release Q1 FY19 Results on July 26, 2018 Business Wire
Jun-28-18 07:35AM  Initiating Free Research Reports on Canopy Growth and Three Other Drug Makers Equities ACCESSWIRE
Jun-25-18 11:23AM  Lilly Wins Favorable Ruling From U.S. Court in Alimta Row Zacks
Jun-21-18 09:25PM  Spotlight On Dr Reddys Laboratories Limiteds (NSE:DRREDDY) Fundamentals Simply Wall St.
Jun-19-18 03:31AM  Dr. Reddy's Laboratories Announces the Launch of Levetiracetam in Sodium Chloride Injection in the U.S. Market Business Wire
Jun-18-18 10:09AM  Company News For Jun 18, 2018 Zacks
Jun-16-18 02:13AM  Dr. Reddy's Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market Business Wire
01:59AM  Dr. Reddys Laboratories Limited announces filing of Annual Report on Form 20-F Business Wire
Jun-15-18 04:58PM  Indivior Finance S.ar.l. -- Moody's places Indivior's ratings under review for downgrade Moody's +6.18%
02:00PM  Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone Zacks
12:00PM  Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market PR Newswire
10:44AM  UK's Indivior will fight U.S. FDA's approval for copycat drug Reuters
08:40AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
06:30AM  Indivior shares dive after Dr Reddy's gets FDA approval for generic Reuters
Jun-14-18 11:06PM  Dr. Reddy's Laboratories Announces USFDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market Business Wire
Jun-09-18 08:13AM  Dr. Reddy's Laboratories Limited to present at the Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
Jun-05-18 09:10AM  Dr. Reddy's Laboratories Limited to Present at the Jefferies 2018 Healthcare Conference Business Wire
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
CNC Centene Corporation daily Stock Chart
CNC [NYSE]
Centene Corporation
IndexS&P 500 P/E24.54 EPS (ttm)2.33 Insider Own4.80% Shs Outstand414.78M Perf Week-3.40%
Market Cap23.70B Forward P/E11.83 EPS next Y4.83 Insider Trans-0.21% Shs Float403.81M Perf Month-10.03%
Income900.00M PEG1.43 EPS next Q1.34 Inst Own92.20% Short Float1.27% Perf Quarter-3.90%
Sales60.12B P/S0.39 EPS this Y13.50% Inst Trans1.60% Short Ratio1.57 Perf Half Y-20.12%
Book/sh26.55 P/B2.15 EPS next Y13.76% ROA3.10% Target Price78.45 Perf Year9.16%
Cash/sh14.62 P/C3.91 EPS next 5Y17.14% ROE9.10% 52W Range50.00 - 74.49 Perf YTD-0.88%
Dividend- P/FCF42.40 EPS past 5Y25.80% ROI5.60% 52W High-23.29% Beta1.29
Dividend %- Quick Ratio1.00 Sales past 5Y40.80% Gross Margin18.20% 52W Low14.28% ATR1.43
Employees47300 Current Ratio1.00 Sales Q/Q29.30% Oper. Margin2.40% RSI (14)37.04 Volatility2.13% 2.54%
OptionableYes Debt/Eq0.61 EPS Q/Q94.00% Profit Margin1.50% Rel Volume1.06 Prev Close58.91
ShortableYes LT Debt/Eq0.61 EarningsApr 23 BMO Payout0.00% Avg Volume3.26M Price57.14
Recom1.90 SMA20-4.26% SMA50-7.60% SMA200-12.99% Volume3,456,787 Change-3.00%
Jan-14-19Initiated Stephens Overweight $147
Oct-24-18Upgrade Leerink Partners Mkt Perform → Outperform
Jul-18-18Resumed Citigroup Neutral $147
Dec-18-17Reiterated Jefferies Buy $112 → $115
Sep-13-17Reiterated Leerink Partners Mkt Perform $78 → $90
Jun-07-17Initiated Morgan Stanley Overweight
May-22-17Downgrade JP Morgan Overweight → Neutral
Apr-05-17Initiated Deutsche Bank Buy $84
Mar-23-17Downgrade Citigroup Buy → Neutral
Feb-08-17Reiterated Barclays Overweight $75 → $79
Feb-07-17Resumed Cantor Fitzgerald Overweight $85
Jan-04-17Initiated Piper Jaffray Overweight
Dec-21-16Initiated JP Morgan Overweight
Dec-13-16Upgrade Goldman Sell → Neutral
Nov-14-16Upgrade Bernstein Mkt Perform → Outperform
Nov-11-16Downgrade Credit Suisse Outperform → Neutral
Sep-06-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-29-16Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-20-16Upgrade Barclays Equal Weight → Overweight $76 → $82
Jun-16-16Initiated Bernstein Mkt Perform
Mar-22-19 05:35PM  Centene sued over unpaid rent in Rancho Cordova American City Business Journals
10:27AM  Zacks Value Trader Highlights: Allstate, Best Buy, Sysco, Walmart and Centene Zacks
09:10AM  Is Centene (CNC) a Great Value Stock Right Now? Zacks
Mar-21-19 11:48AM  The Secret Value Stock Screen to Use Now Zacks
Mar-20-19 11:13AM  WellCare Health Arm MeridianRx Unveils Mobile Application Zacks
11:02AM  Universal Health's Acute Care Segment Solid, High Debt Ails Zacks
Mar-18-19 11:11AM  HCA Healthcare to Buy Large Stake in Galen College of Nursing Zacks
09:30AM  Is Centene (CNC) Stock Outpacing Its Medical Peers This Year? Zacks
09:03AM  Humana, Accolade to Team Up for Providing Advanced Healthcare Zacks
Mar-15-19 10:58AM  Why is it Worth Keeping Humana (HUM) in Your Portfolio Now? Zacks
Mar-13-19 05:02AM  7 Fast-Revenue Growth Stocks to Lead as S&P 500 Slows Investopedia
Mar-11-19 05:50PM  Centene (CNC) Outpaces Stock Market Gains: What You Should Know Zacks
10:39AM  Here's Why You Should Add Tenet Healthcare to Your Portfolio Zacks
10:12AM  Magellan Health Down Nearly 40%, in a Year: What's Next? Zacks
Mar-07-19 09:30AM  Centene (CNC) Down 9.8% Since Last Earnings Report: Can It Rebound? Zacks
08:30AM  Arm of Ensign Group Unit Buys All County Home Care and Hospice Zacks
08:28AM  Why Anthem (ANTM) is an Attractive Pick for Your Portfolio Zacks
Mar-06-19 03:46PM  Coltene Growing With Global Dentistry Boom GuruFocus.com
10:10AM  Ensign Group Buys Nursing Hub to Expand in South California Zacks
09:10AM  Should Value Investors Buy Centene (CNC) Stock? Zacks
Mar-05-19 07:15AM  Report: Developing Opportunities within Gray Television, Terex, Marriott International, Philip Morris International, Nordstrom, and Centene Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-04-19 01:50PM  Is Centenes 282% Share Price Increase Well Justified? Simply Wall St.
08:15AM  Centene To Present At Two Upcoming Healthcare Conferences In March PR Newswire
Mar-01-19 03:20PM  Health Net Assisting Members in 25 California Counties During State of Emergency Business Wire
09:27AM  The Wonderful Co. buys Centene-leased buildings for $36.9 million American City Business Journals
07:37AM  3 Big Stock Charts for Friday: Eli Lilly, Centene and LKQ Corporation InvestorPlace
Feb-28-19 04:22PM  Reminder: Centene Corporation's 2019 First Quarter Financial Results Conference Call PR Newswire
09:45AM  Universal Health's (UHS) Q4 Earnings Beat Estimates, Up Y/Y Zacks
08:34AM  Teladoc (TDOC) Q4 Earnings Meet Estimates, Revenues Beat Zacks
07:44AM  With biggest deal, St. Louis leads the way in M&A American City Business Journals
Feb-27-19 08:49PM  What's Keeping You Up?: Cramer's 'Mad Money' Recap (Wednesday 2/27/19) TheStreet.com
09:19AM  Here's Why You Should Add Ensign Group to Your Portfolio Now Zacks
Feb-26-19 09:29AM  Tenet Healthcare (THC) Q4 Earnings Beat Estimates, Down Y/Y Zacks
Feb-22-19 07:00AM  Centene Corporation Announces Formation Of Social Health Bridge To Address Social Determinants Of Health PR Newswire
Feb-21-19 05:50PM  Centene CEO visits planned corporate campus, expresses enduring commitment to Sacramento American City Business Journals
05:18PM  Lee Ainslie's Top 5 Buys for the 4th Quarter GuruFocus.com
03:30PM  Centene Dedicates Cornerstone Of New Sacramento Campus PR Newswire
Feb-20-19 03:36PM  A national health care giant seeks a chunk of the Portland metro Medicaid business American City Business Journals
02:09PM  CVS Health Corp (CVS) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-19-19 05:49PM  Centene Corp (CNC) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
10:43AM  Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR Zacks
09:40AM  Here's Why You Should Add Centene (CNC) to Your Portfolio Zacks
Feb-15-19 02:30PM  John Muir Middle School and Health Net Celebrate National No One Eats Alone Day Business Wire
08:18AM  Ride on Rising P/E Investing With These 5 Top-Ranked Stocks Zacks
Feb-14-19 08:38AM  Here's Why Investing in Molina Healthcare (MOH) Makes Sense Zacks
06:38AM  Should You Be Happy With Centene Corporations (NYSE:CNC) 8.7% Earnings Growth? Simply Wall St.
Feb-11-19 09:30AM  Has Centene (CNC) Outpaced Other Medical Stocks This Year? Zacks
07:00AM  Centene Corporation Announces Envolve Center Name Change To The Centene Center for Health Transformation PR Newswire
Feb-08-19 07:25AM  Analysis: Positioning to Benefit within National Oilwell Varco, Centene, Paylocity Holding, NorthStar Realty Europe, Geron, and NACCO Industries Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-07-19 01:01PM  The Shuman Law Firm Investigates Centene Corp. Business Wire
09:45AM  Centene Splits 2 For 1 Which Changes the Chart Levels but Not the Trends TheStreet.com
06:00AM  Centene Corporation Announces Two-For-One Stock Split Is Effective PR Newswire
Feb-06-19 07:16PM  Edited Transcript of CNC earnings conference call or presentation 5-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
07:10PM  Cramer Remix: After a 20-year hiatus, this stock is finally back CNBC
07:06PM  Centene CEO addresses State of the Union, says US 'can't afford' some 2020 candidates' health-care proposals CNBC Videos
11:05AM  Inside Centene: A big deal that worked and a growing geographic reach American City Business Journals
09:10AM  Is Centene (CNC) Stock Undervalued Right Now? Zacks
Feb-05-19 04:35PM  Centene Corp (CNC) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Centene, WellCare Earnings Top As Health Insurers Work On Buy Points Investor's Business Daily
01:19PM  IBD 50 Stocks To Watch: Blue Chip UnitedHealth Shapes Bullish Base Investor's Business Daily
12:28PM  N.Y. deal helped push Centene past $60B in 2018 American City Business Journals
12:22PM  Centene Stock Rises Following Earnings Beat and Guidance Boost TheStreet.com
09:22AM  Centene's (CNC) Earnings Top Estimates in Q4, Surge Y/Y Zacks
09:18AM  US STOCKS-Wall St set to rise at open, Trump's State of the Union speech in focus Reuters
08:45AM  Zacks.com featured highlights include: Molina, Dana, DICK???S, Centene and Covenant Zacks
07:49AM  Stocks making the biggest moves premarket: Viacom, Centene, Merck, Alphabet & more CNBC
07:30AM  Centene (CNC) Surpasses Q4 Earnings and Revenue Estimates Zacks
06:30AM  Centene: 4Q Earnings Snapshot Associated Press
06:00AM  Centene Corporation Reports 2018 Results And Increases 2019 Annual Guidance PR Newswire
Feb-04-19 08:53PM  8 Earnings to Watch Before the Market Opens Tuesday TheStreet.com
06:03PM  Centene, North Carolina Medical Society And North Carolina Community Health Center Association Awarded Medicaid Contract PR Newswire
08:38AM  5 Stocks That Brokers Currently Love: Do You? Zacks
Feb-01-19 03:16PM  State builders, construction unions working on deal to ease pay, CEQA requirements American City Business Journals
09:25AM  What Lies Ahead for Centene (CNC) Stock in Q4 Earnings? Zacks
07:00AM  Centene recognized by CMS with Health Equity Award PR Newswire
Jan-31-19 01:00PM  Health Net Awards $1.2 Million in Grants in California to Increase Access to Healthcare and Improve Health Outcomes Business Wire
Jan-29-19 05:50PM  Centene (CNC) Dips More Than Broader Markets: What You Should Know Zacks
10:31AM  Centene (CNC) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jan-28-19 10:16AM  Why Centene Corporations (NYSE:CNC) High P/E Ratio Isnt Necessarily A Bad Thing Simply Wall St.
Jan-23-19 05:50PM  Centene (CNC) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-22-19 02:43PM  Centene CEO weighs in on the impact of ACA ending Yahoo Finance Video
08:00AM  Magnolia Health Implements RxAdvance's Transformative Pharmacy Benefit Management Model PR Newswire
07:00AM  Centene Subsidiary Selected To Provide Comprehensive Medical Services To Arizona Department Of Corrections PR Newswire
Jan-17-19 10:10AM  Will Centene (CNC) Beat Estimates Again in Its Next Earnings Report? Zacks
Jan-15-19 11:53AM  Centene shuffles leadership after $3 billion New York acquisition American City Business Journals
08:10AM  The Zacks Analyst Blog Highlights: Centene, Archer Daniels Midland, Spirit Airlines, Pinnacle West and Walmart Zacks
07:00AM  Centene Corporation Announces Appointments PR Newswire
Jan-14-19 08:49AM  Recession Risk Hits 7-Year High: 5 Secure Picks Zacks
Jan-11-19 09:30AM  Has Centene (CNC) Outpaced Other Medical Stocks This Year? Zacks
09:10AM  Is Centene (CNC) a Great Value Stock Right Now? Zacks
Jan-10-19 07:10AM  Jim Cramer Weighs In On AutoZone, Chevron, Turtle Beach And More Benzinga
Jan-08-19 04:15PM  Reminder: Centene Corporation's 2018 Fourth Quarter And Full Year Financial Results Conference Call PR Newswire
11:06AM  Centene Corporation (NYSE:CNC) Insiders Have Been Selling Simply Wall St.
Jan-07-19 07:25AM  Report: Exploring Fundamental Drivers Behind Spectrum Brands, Amgen, MSCI, Diamondback Energy, Centene, and Paramount Group New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-04-19 02:31PM  American Railcar leads 12 St. Louis stocks that finished higher in a bad year American City Business Journals
09:56AM  Molina Renews Pact With CVS to Boost PBM Service Platform Zacks
Dec-31-18 09:53AM  Here are the health care stocks to watch in 2019 CNBC Videos
Dec-28-18 05:36PM  Looking Ahead: Health industry to see new jobs, facilities in 2019 American City Business Journals
08:00AM  Centene Corporation Announces Purchase Of Stake In University Hospital of Torrejón In Madrid PR Newswire
Dec-25-18 09:10AM  Is Centene (CNC) a Great Value Stock Right Now? Zacks
Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. The company's Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which covers dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions, limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. Its Specialty Services segment provides pharmacy benefits management services; health, triage, wellness, and disease management services; and vision and dental, and management services, as well as care management software that automate the clinical, administrative, and technical components of care management programs. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOWERS CHRISTOPHER DEVP, MarketsFeb 15Sale65.019,200598,092121,898Feb 19 05:10 PM
Schwaneke Jeffrey A.EVP, CFOJan 15Sale125.004,000500,000170,840Jan 17 05:40 PM
NEIDORFF MICHAEL FChairman & CEODec 18Option Exercise57.0210,000570,2003,699,611Dec 18 07:31 PM
Hunter Jesse NEVP, M&A & Chief Strategy OfcrDec 18Sale121.2610,0001,212,600226,382Dec 20 05:05 PM
BROOKS MARK JEVP, Chief Information OfficerDec 18Sale121.262,540308,00058,868Dec 20 05:02 PM
DITMORE ROBERT KDirectorOct 25Sale129.2415,0001,938,600433,797Oct 29 04:44 PM
Williamson Keith HEVP, Secr. & General CounselSep 28Sale145.002,000290,00088,658Oct 02 07:02 PM
GEPHARDT Richard ADirectorSep 10Sale145.552,000291,10040,624Sep 12 05:26 PM
DITMORE ROBERT KDirectorSep 10Sale145.0615,0002,175,900448,491Sep 12 05:23 PM
BOWERS CHRISTOPHER DEVP, MarketsSep 10Sale145.553,800553,09061,894Sep 12 05:21 PM
DITMORE ROBERT KDirectorJul 26Sale131.448,7501,150,100463,491Jul 30 05:55 PM
Hunter Jesse NEVP & Chief Strategy OfficerJul 26Sale131.905,000659,500228,629Jul 30 05:47 PM
BURKHALTER BRANDYEVP, OperationsJul 26Sale131.903,000395,70091,663Jul 30 05:45 PM
Williamson Keith HEVP, Secr. & General CounselJun 11Sale120.002,000240,00090,658Jun 11 05:27 PM
ROBERTS JOHN RDirectorMay 07Option Exercise8.4510,00084,500116,913May 08 06:13 PM
Williamson Keith HEVP, Secr. & General CounselMay 02Sale115.001,000115,00092,658May 04 05:20 PM
Williamson Keith HEVP, Secr. & General CounselApr 27Sale110.001,000110,00093,658Apr 27 08:14 PM
Hunter Jesse NEVP & Chief Strategy OfficerApr 26Sale108.345,000541,700233,629Apr 27 08:05 PM
DITMORE ROBERT KDirectorApr 26Sale108.158,750946,313471,918Apr 27 08:03 PM
NEIDORFF MICHAEL FChairman & CEOApr 26Sale108.20250,00027,050,0003,625,571Apr 27 08:12 PM
Hunter Jesse NEVP & Chief Strategy OfficerApr 04Option Exercise8.428,00067,360242,604Apr 05 06:30 PM
SPB Spectrum Brands Holdings, Inc. daily Stock Chart
SPB [NYSE]
Spectrum Brands Holdings, Inc.
Index- P/E9.26 EPS (ttm)6.00 Insider Own15.00% Shs Outstand53.40M Perf Week-1.58%
Market Cap2.96B Forward P/E13.55 EPS next Y4.10 Insider Trans0.00% Shs Float52.99M Perf Month-0.79%
Income134.10M PEG0.69 EPS next Q0.51 Inst Own31.07% Short Float7.34% Perf Quarter27.72%
Sales3.10B P/S0.96 EPS this Y198.80% Inst Trans13.26% Short Ratio5.81 Perf Half Y-31.79%
Book/sh26.17 P/B2.12 EPS next Y50.96% ROA- Target Price67.14 Perf Year-40.31%
Cash/sh- P/C- EPS next 5Y13.40% ROE- 52W Range40.54 - 103.07 Perf YTD31.41%
Dividend1.68 P/FCF- EPS past 5Y30.20% ROI10.10% 52W High-46.13% Beta1.90
Dividend %3.03% Quick Ratio0.90 Sales past 5Y-10.70% Gross Margin37.20% 52W Low36.95% ATR1.77
Employees13000 Current Ratio1.10 Sales Q/Q-4.90% Oper. Margin- RSI (14)52.37 Volatility2.65% 3.06%
OptionableYes Debt/Eq3.38 EPS Q/Q-117.40% Profit Margin- Rel Volume0.63 Prev Close56.40
ShortableYes LT Debt/Eq1.85 EarningsFeb 07 BMO Payout- Avg Volume668.73K Price55.52
Recom2.20 SMA200.67% SMA502.88% SMA200-17.38% Volume424,489 Change-1.56%
Jan-18-19Upgrade BofA/Merrill Neutral → Buy
Nov-20-18Reiterated Monness Crespi & Hardt Buy $103 → $64
Nov-20-18Downgrade Raymond James Outperform → Mkt Perform
Nov-19-18Downgrade Oppenheimer Outperform → Perform
Jul-20-18Initiated BofA/Merrill Neutral $84
Apr-27-18Reiterated Monness Crespi & Hardt Buy $137 → $103
Apr-26-18Downgrade Wells Fargo Outperform → Market Perform
Nov-17-17Upgrade Gabelli & Co Hold → Buy
Oct-31-17Resumed Wells Fargo Outperform $125
Mar-14-17Initiated RBC Capital Mkts Outperform $160
Jan-10-17Downgrade BofA/Merrill Buy → Neutral
Oct-13-16Reiterated Jefferies Buy $157 → $160
Sep-29-16Reiterated Monness Crespi & Hardt Buy $138 → $151
Sep-01-16Initiated Piper Jaffray Overweight $147
Jul-29-16Reiterated Monness Crespi & Hardt Buy $125 → $138
Apr-29-16Reiterated Monness Crespi & Hardt Buy $114 → $125
Jan-08-16Upgrade Jefferies Hold → Buy
Dec-15-15Initiated Raymond James Outperform
Aug-06-15Reiterated Deutsche Bank Buy $112 → $114
Jul-09-15Initiated Gabelli & Co Hold $124
Mar-22-19 10:30AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SPB, MHLD, AMR and MBT GlobeNewswire
Mar-21-19 08:06PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. Business Wire
05:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline  SPB GlobeNewswire
02:10PM  SHAREHOLDER ALERT: SPB MHLD MBT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
12:25PM  Robbins Arroyo LLP: Spectrum Brands Holdings Inc. (SPB) Sued for Misleading Shareholders Business Wire
11:00AM  SHAREHOLDER ALERT: SPB TAP CTL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
Mar-20-19 09:29PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. Business Wire
09:42AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, ASTE, VALE and AVEO GlobeNewswire
07:03AM  Should Invesco Russell 1000 Equal Weight ETF (EQAL) Be on Your Investing Radar? Zacks
Mar-19-19 08:23PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. Investors Business Wire
05:59PM  CLASS ACTION UPDATE for SPB, ARLO, MU and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
05:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline SPB ACCESSWIRE
Mar-18-19 04:27PM  Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. Investors (SPB) Business Wire
02:59PM  SHAREHOLDER ALERT: SPB ATVI BRS UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
02:10PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. Investors Business Wire
Mar-17-19 11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SPB, TYME and STMP ACCESSWIRE
Mar-15-19 09:39PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline - SPB PR Newswire
04:15PM  SPECTRUM BRANDS LEGACY, INC. F/K/A SPECTRUM BRANDS HOLDINGS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Wisconsin GlobeNewswire
03:55PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, BRS and AMRN ACCESSWIRE
02:57PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. To Contact The Firm GlobeNewswire
11:45AM  CLASS ACTION UPDATE for SPB, MU and CTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
Mar-14-19 05:47PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. Investors Business Wire
10:56AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, KHC, CTL and CNDT GlobeNewswire
Mar-13-19 08:01PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. Investors GlobeNewswire
03:26PM  CLASS ACTION UPDATE for SPB, ARLO, AMRN and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:33AM  Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. (SPB) GlobeNewswire
10:10AM  SHAREHOLDER ALERT: SPB GE AVP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
Mar-12-19 05:29PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Spectrum Brands Legacy, Inc. (f/k/a Spectrum Brands Holdings, Inc.) Business Wire
11:04AM  SHAREHOLDER ALERT: SPB BRS STMP BPI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Mar-11-19 05:55PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. (SPB) ACCESSWIRE
03:28PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SPB, MHLD, SYNH and CNDT GlobeNewswire
02:50PM  Pomerantz Law Firm Announces the Filing of a Class Action against Spectrum Brands Legacy, Inc. f/k/a Spectrum Brands Holdings, Inc. SPB GlobeNewswire
01:32PM  K-9 Veterans Day 2019 Introduces Dog-Friendly American Flag and Facebook Awareness Campaign for Wednesday, March 13 PR Newswire
Mar-10-19 10:20AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SPB, ZIV and W ACCESSWIRE
Mar-09-19 08:31AM  HRG (SPB) Up 17.4% Since Last Earnings Report: Can It Continue? Zacks
Mar-08-19 04:05PM  CLASS ACTION UPDATE for SPB, VALE and DPLO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:01AM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Spectrum Brands Holdings, Inc. (SPB) and Encourages SPB Investors to Contact the Firm GlobeNewswire
Mar-07-19 05:14PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Spectrum Brands Legacy, Inc. (f/k/a Spectrum Brands Holdings, Inc.) Investors and Sets a Lead Plaintiff Deadline of May 6, 2019 GlobeNewswire
Mar-06-19 08:15AM  Detailed Research: Economic Perspectives on KAR Auction Services, Spectrum Brands, Vertex Pharmaceuticals, The Kraft Heinz, comScore, and Retrophin What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-05-19 04:03PM  Spectrum Brands Global Pet Care Division Highlights Heritage of Innovation Inside Every Product for 2019 Global Pet Expo Showcase PR Newswire
06:30AM  Spectrum Brands Holdings to Reaffirm Fiscal 2019 Guidance at Raymond James Institutional Investors Conference Business Wire
Feb-28-19 06:30AM  Spectrum Brands Holdings to Present at Raymond James 40th Annual Institutional Investors Conference Business Wire
Feb-26-19 07:00AM  Spectrum Brands, Inc. Showcases Its Newest Product Offerings From Top Consumer Brands at the 2019 International Home + Housewares Show Business Wire
Feb-21-19 06:30AM  Spectrum Brands Holdings to Reaffirm Fiscal 2019 Guidance at CAGNY Conference Business Wire
Feb-19-19 08:00AM  Baldwin® Hardware, A Leading Brand of the Hardware & Home Improvement Division of Spectrum Brands, Stuns With Luxury Smart Security Solutions at NAHB International Builders Show® GlobeNewswire
Feb-12-19 07:55AM  New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
06:30AM  Spectrum Brands Holdings to Present at 2019 CAGNY Conference Business Wire
Feb-08-19 11:01PM  Edited Transcript of SPB earnings conference call or presentation 7-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
09:30AM  Company News For Feb 8, 2019 Zacks
08:53AM  Spectrum Brands (SPB) Stock Down 18% on Q1 Loss & Sales Miss Zacks
Feb-07-19 06:12PM  A Surprise Q1 Loss and Weak Top-Line Results Send Spectrum Brands 17.7% Lower Thursday Motley Fool -17.67%
02:33PM  Spectrum Brands Holdings Inc (SPB) Q1 2019 Earnings Conference Call Transcript Motley Fool
07:45AM  Spectrum Brands (SPB) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:45AM  Spectrum Brands reports surprise loss as sales fall more than expected MarketWatch
06:40AM  HRG: Fiscal 1Q Earnings Snapshot Associated Press
06:30AM  Spectrum Brands Holdings Reports Fiscal 2019 First Quarter Results from Continuing Operations and Reiterates Full-Year Guidance Business Wire
04:00AM  Spectrum Brands Holdings and Manchester United plc Announce Multi-Year, Global Partnership for Remington® Personal Care Brand Business Wire
Feb-05-19 04:34PM  Energizer Holdings Inc (ENR) Q1 2019 Earnings Conference Call Transcript Motley Fool
Feb-01-19 10:22AM  Factors Likely to Shape Spectrum Brands' (SPB) Q1 Earnings Zacks
09:29AM  Should Invesco Russell 1000 Equal Weight ETF (EQAL) Be on Your Investing Radar? Zacks
Jan-31-19 10:31AM  Spectrum Brands (SPB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Jan-29-19 09:11AM  Energizer Closes Buyout of Spectrum Brands' GAC Business Zacks
Jan-28-19 06:01PM  Spectrum Brands Holdings Declares Quarterly Common Stock Dividend of $0.42 Per Share Business Wire
01:44PM  Spectrum Brands closes $1.25 billion sale of more of its consumer brands American City Business Journals
10:06AM  Spectrum Brands Holdings Announces Closing of the Sale of its Global Auto Care Business to Energizer Holdings, Inc. Business Wire
Jan-23-19 12:39PM  GloFish® Brand Brightens Kenyan Community's Health, Sustainable Future PR Newswire
Jan-22-19 03:35PM  10 Consumer Stocks to Buy for Income InvestorPlace
Jan-16-19 12:05PM  Energizer Gamma Acquisition B.V. -- Moody's confirms Energizer's B1 CFR; outlook stable Moody's
Jan-15-19 02:47PM  GloFish® Brand of Spectrum Brands Pet LLC Announces Electric Green® Long-Fin Barbs PR Newswire
Jan-11-19 06:30AM  Spectrum Brands Holdings to Report Fiscal 2019 First Quarter Financial Results and Hold Conference Call and Webcast on February 7 Business Wire
Jan-08-19 11:00AM  Baldwin® Hardware, a Leading Brand of the Hardware & Home Improvement Division of Spectrum Brands, Goes Keyless in Vegas With Luxurious New Smart Lock Security Solutions GlobeNewswire
09:00AM  Kwikset Introduces New Halo Wi-Fi Smart Locks Exclusively at CES 2019 PR Newswire
Jan-07-19 07:25AM  Report: Exploring Fundamental Drivers Behind Spectrum Brands, Amgen, MSCI, Diamondback Energy, Centene, and Paramount Group New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-04-19 04:30PM  Spectrum Brands Completes Prepayment in Full of All Credit Facility Term Loans in First Step to Materially Strengthen its Balance Sheet Business Wire
Jan-03-19 09:48AM  Stock Market News For Jan 3, 2019 Zacks
05:51AM  Spectrum Brands Closes Sale of Battery Business to Energizer Zacks
Jan-02-19 04:01PM  Spectrum completes $2B sale of battery business to Energizer American City Business Journals
01:05PM  Spectrum Brands Holdings Announces Closing of the Sale of its Global Battery and Lighting Business to Energizer Holdings, Inc. Business Wire
Dec-24-18 09:31AM  Stock Market News For Dec 24, 2018 Zacks
07:23AM  Spectrum Brands' GAC Unit Sale Receives Regulators' Nod Zacks
Dec-21-18 01:02PM  Energizer's $1.25 billion buy of Spectrum's auto care business clears regulators American City Business Journals
06:55AM  Energizer Holdings And Spectrum Brands Holdings Announce Updates With Respect To Energizer's Acquisition Of Spectrum Brands' Auto Care Business PR Newswire
Dec-19-18 09:30AM  HRG (SPB) Down 10.2% Since Last Earnings Report: Can It Rebound? Zacks
Dec-18-18 10:22AM  Spectrum Brands Down 58% YTD: Is a Reversal Likely in 2019? Zacks
Dec-13-18 10:58PM  Do Hedge Funds Love Spectrum Brands Holdings, Inc. (SPB)? Insider Monkey
Dec-12-18 07:50AM  New Research: Key Drivers of Growth for General Mills, Hess, Roku, Spectrum Brands, Texas Pacific Land Trust, and Workday Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-11-18 04:40PM  Energizer wins conditional EU okay for Spectrum buy Reuters
12:31PM  Energizer and Spectrum Brands Announce Clearance from European Commission for Energizer's Acquisition of Spectrum Brands' Battery and Portable Lighting Business PR Newswire
Dec-10-18 10:52PM  Why Both Energizer and Spectrum Brands Shares Fell 24% Last Month Motley Fool
Nov-28-18 05:08PM  GloFish® Brand of Spectrum Brands Pet LLC Expands Fluorescent Fish Offerings in Canada PR Newswire
Nov-23-18 08:48AM  Spectrum Brands Holdings Inc (SPB) Files 10-K for the Fiscal Year Ended on September 30, 2018 GuruFocus.com
Nov-22-18 09:43AM  Taking A Look At Spectrum Brands Holdings Incs (NYSE:SPB) ROE Simply Wall St.
Nov-20-18 09:54AM  Company News For Nov 20, 2018 Zacks
08:58AM  Spectrum Brands (SPB) Stock Down on Q4 Earnings & Sales Miss Zacks
06:50AM  Today's Research Reports on Trending Tickers: Netflix and Spectrum Brands ACCESSWIRE
Nov-19-18 06:09PM  Spectrum Brands Tumbles on Monday GuruFocus.com -19.04%
05:02PM  Why NVIDIA, Spectrum Brands Holdings, and Facebook Slumped Today Motley Fool
04:31PM  PG&E and Spectrum Brands fall while Resolute Energy rises Associated Press
01:51PM  Edited Transcript of SPB earnings conference call or presentation 19-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
01:45PM  Spectrum Brands Holdings, Inc. (SPB) Q4 2018 Earnings Conference Call Transcript Motley Fool
Spectrum Brands Holdings, Inc. operates as a branded consumer products company worldwide. The company's Hardware & Home Improvement segment offers hardware products under the National Hardware, Stanley, and FANAL brands; locksets and door hardware under the Kwikset, Weiser, Baldwin, EZSET, and Tell brands; and plumbing products under the Pfister brand. Its Global Pet Supplies segment provides dog, cat, and small animal food and treats; clean-up and training aid products and accessories; and pet health and grooming products under the 8IN1 (8-in-1), Dingo, Nature's Miracle, Wild Harvest, Littermaid, Jungle, Excel, FURminator, IAMS, Eukanuba, Healthy-Hide, DreamBone, SmartBones, GloFish, ProSense, Perfect Coat, eCOTRITION, Birdola, and Digest-eeze brands. It also offers aquariums and aquatic health supplies under the Tetra, Marineland, Whisper, and Instant Ocean brand names. The company's Home and Garden segment provides outdoor insect and weed control solutions, and animal repellents under the Spectracide, Garden Safe, Liquid Fence, and EcoLogic brands; household pest controls under the Hot Shot, Black Flag, Real-Kill, Ultra Kill, The Ant Trap, and Rid-A-Bug brand names; and personal-use pesticides under the Cutter and Repel brands. Its Global Auto Care segment offers protectants, wipes, tire and wheel care products, glass cleaners, leather care products, air fresheners, and washes under the Armor All brand; automotive fuel and oil additives, and functional fluids under the STP brand name; and do-it-yourself air conditioner recharge products, refrigerant and oil recharge kits, sealants, and accessories under the A/C PRO brand. The company sells its products through retailers, e-commerce and online retailers, wholesalers and distributors, construction companies, and original equipment manufacturers. The company was formerly known as HRG Group, Inc. and changed its name to Spectrum Brands Holdings, Inc. in July 2018. The company is headquartered in Middleton, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ambrecht Kenneth CDirectorJun 05Buy80.571078,63923,202Jul 17 04:02 PM
AGIO Agios Pharmaceuticals, Inc. daily Stock Chart
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.03 Insider Own0.30% Shs Outstand57.05M Perf Week-4.18%
Market Cap3.55B Forward P/E- EPS next Y-6.02 Insider Trans-18.23% Shs Float50.85M Perf Month10.97%
Income-346.00M PEG- EPS next Q-1.75 Inst Own- Short Float15.35% Perf Quarter25.81%
Sales94.40M P/S37.64 EPS this Y10.80% Inst Trans3.35% Short Ratio16.21 Perf Half Y-14.08%
Book/sh11.81 P/B5.27 EPS next Y11.60% ROA-36.20% Target Price86.56 Perf Year-28.01%
Cash/sh10.26 P/C6.07 EPS next 5Y- ROE-44.10% 52W Range41.63 - 99.82 Perf YTD35.09%
Dividend- P/FCF- EPS past 5Y-16.40% ROI- 52W High-37.60% Beta2.39
Dividend %- Quick Ratio6.60 Sales past 5Y29.90% Gross Margin98.50% 52W Low49.63% ATR2.76
Employees482 Current Ratio6.60 Sales Q/Q206.10% Oper. Margin- RSI (14)50.27 Volatility4.26% 4.29%
OptionableYes Debt/Eq0.00 EPS Q/Q12.80% Profit Margin- Rel Volume0.73 Prev Close65.59
ShortableYes LT Debt/Eq0.00 EarningsFeb 14 BMO Payout- Avg Volume481.40K Price62.29
Recom2.00 SMA20-3.28% SMA506.62% SMA200-10.25% Volume352,306 Change-5.03%
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
May-18-16Reiterated Sun Trust Rbsn Humphrey Buy $57 → $65
Mar-30-16Initiated Sun Trust Rbsn Humphrey Buy $57
Jan-21-16Initiated Credit Suisse Outperform
Dec-07-15Downgrade Leerink Partners Outperform → Mkt Perform
Nov-09-15Reiterated ROTH Capital Neutral $114 → $75
Mar-16-19 09:30AM  Why Is Agios Pharmaceuticals (AGIO) Up 13.2% Since Last Earnings Report? Zacks
Mar-06-19 02:01PM  All You Need To Know About Agios Pharmaceuticals, Inc.s (NASDAQ:AGIO) Financial Health Simply Wall St. -6.11%
Mar-04-19 07:00AM  Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 GlobeNewswire
Feb-25-19 07:00AM  Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients GlobeNewswire +5.93%
Feb-22-19 07:25AM  Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-21-19 09:34AM  Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer Zacks
07:00AM  Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019 GlobeNewswire
Feb-20-19 03:43PM  Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
07:00AM  Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy GlobeNewswire
Feb-15-19 02:25PM  Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock Zacks
Feb-14-19 12:01PM  Agios Pharmaceuticals Inc (AGIO) Q4 2018 Earnings Conference Call Transcript Motley Fool +6.27%
09:10AM  Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates Zacks
08:10AM  Agios Pharmaceuticals: 4Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-11-19 12:09PM  Agios ex-CEO joins GV as life sciences investment team's co-head American City Business Journals
Feb-07-19 10:31AM  Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jan-29-19 01:52PM  Have Insiders Been Selling Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares? Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-07-19 07:00AM  Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value GlobeNewswire +8.70%
Dec-28-18 07:00AM  Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 GlobeNewswire
Dec-14-18 12:03PM  Our Take On Agios Pharmaceuticals, Inc.s (NASDAQ:AGIO) CEO Salary Simply Wall St.
Dec-13-18 07:20AM  Market Trends Toward New Normal in DXC Technology, Patterson Companies, Lumentum, DSW, Agios Pharmaceuticals, and Six Flags Entertainment Corporation New Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
03:20AM  Hedge Funds Are Selling Agios Pharmaceuticals Inc (AGIO) Insider Monkey
Dec-12-18 07:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals ACCESSWIRE
Dec-08-18 05:36PM  Could These Be the Next 2 Biotech Buyouts? Motley Fool
Dec-07-18 07:00AM  Today's Research Reports on Trending Tickers: Amarin Corporation and Agios Pharmaceuticals ACCESSWIRE -5.37%
Dec-03-18 10:30AM  Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS) GlobeNewswire -13.66%
10:15AM  Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis ACCESSWIRE
Nov-26-18 07:05AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Amarin Corporation ACCESSWIRE
Nov-19-18 05:00AM  Edited Transcript of AGIO earnings conference call or presentation 1-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
Nov-16-18 07:00AM  Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma GlobeNewswire
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals ACCESSWIRE
Nov-08-18 08:00AM  New Research Coverage Highlights John B. Sanfilippo & Son, Axcelis Technologies, Cogent Communications, Star Bulk Carriers, Agios Pharmaceuticals, and MDC Partners Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-02-18 01:01PM  Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock Zacks
Nov-01-18 10:41AM  Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Tops Revenue Estimates Zacks +8.64%
09:20AM  Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting GlobeNewswire
08:22AM  Agios Pharmaceuticals: 3Q Earnings Snapshot Associated Press
08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte ACCESSWIRE
07:00AM  Agios Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-19-18 11:44AM  Agios Rides on Tibsovo Approval Amid Reliance on Celgene Zacks
Oct-18-18 07:00AM  Agios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018 GlobeNewswire -6.62%
Oct-04-18 07:50AM  New Research Coverage Highlights Camden Property Trust, Agios Pharmaceuticals, Crane, BorgWarner, Cognizant Technology Solutions, and Liberty Broadband Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-01-18 06:35AM  After auspicious run at Agios, biotech exec David Schenkein mulls future American City Business Journals
Sep-19-18 09:37AM  Is Agios Pharmaceuticals Inc (NASDAQ:AGIO) Worth US$71.67 Based On Intrinsic Value? Simply Wall St.
Sep-06-18 08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical ACCESSWIRE
Sep-05-18 10:21AM  Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position Zacks
08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
Sep-04-18 06:33PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
06:12PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
05:57PM  Agios Announces Chief Executive Officer Succession Plan GlobeNewswire
04:53PM  [$$] Agios Pharmaceuticals Plans to Pump Cash Into R&D The Wall Street Journal
Aug-28-18 07:00AM  Agios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018 GlobeNewswire
Aug-17-18 11:49PM  Edited Transcript of AGIO earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-13-18 09:30AM  Opening Bell, August 13, 2018 CNBC Videos
Aug-03-18 11:55AM  Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates Zacks
Aug-02-18 09:25AM  Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates Zacks -7.29%
08:47AM  Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates Zacks
08:19AM  Agios Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-30-18 11:25AM  What's in the Cards for Agios (AGIO) Stock in Q2 Earnings? Zacks
Jul-25-18 08:12AM  Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug Zacks
Jul-23-18 11:26AM  Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo Zacks
07:00AM  Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018 GlobeNewswire
Jul-20-18 02:46PM  Cambridge's Agios wins FDA approval for second cancer drug American City Business Journals
10:59AM  FDA approves Agios Pharmaceuticals leukemia drug Reuters
10:45AM  FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation GlobeNewswire
Jun-29-18 07:50AM  Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals, Roadrunner Transportation, and OSI Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-27-18 11:32AM  Agios Out-Licenses China Rights to Leukemia Drug Tibsovo Zacks
Jun-26-18 08:16AM  BRIEF-Agios And CStone Pharmaceuticals Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Ivosidenib In Greater China Reuters -5.30%
08:00AM  Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China GlobeNewswire
Jun-21-18 08:39AM  Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street Benzinga
Jun-20-18 03:54AM  Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug Zacks
Jun-18-18 07:00AM  Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused GlobeNewswire
Jun-05-18 12:04PM  Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason InvestorPlace
Jun-04-18 09:00AM  New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients GlobeNewswire
05:43AM  Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue? Zacks
Jun-02-18 04:05PM  Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent GlobeNewswire
Jun-01-18 04:15PM  Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors GlobeNewswire
08:30AM  Today's Research Reports on Trending Tickers: Tesaro and Agios Pharmaceuticals ACCESSWIRE
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 04:04PM  Investors Should Own Agios For 'The Next Several Years,' Analyst Says Benzinga
May-30-18 03:17PM  Agios Pharmaceuticals Has Emerged From a 2-Year Base Pattern TheStreet.com
May-24-18 04:18PM  Agios (AGIO) Progressing Well on Pipeline Amid Competition Zacks
May-17-18 07:50AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-16-18 05:02PM  Agios to Present New Clinical Data from its IDH Programs at ASCO GlobeNewswire
May-07-18 03:28PM  Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss Zacks
May-04-18 07:42AM  Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss Zacks
07:09AM  Agios Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day GlobeNewswire
Apr-30-18 11:37AM  Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings? Zacks
Apr-27-18 07:00AM  Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018 GlobeNewswire
Apr-18-18 09:58AM  Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline Zacks
Apr-16-18 08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
Apr-11-18 07:00AM  Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018 GlobeNewswire
Apr-10-18 11:23AM  Agios Pharmaceuticals Shares Rise on Buyout Speculation Zacks
Apr-09-18 04:32PM  Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today Motley Fool +9.26%
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bowden ChristopherChief Medical OfficerMar 15Option Exercise35.1610,000351,60017,238Mar 19 04:25 PM
Bowden ChristopherChief Medical OfficerMar 15Sale64.1610,000641,6157,238Mar 19 04:25 PM
Biller ScottChief Scientific OfficerMar 05Option Exercise38.603,000115,80529,511Mar 07 04:06 PM
Biller ScottChief Scientific OfficerMar 05Sale67.683,000203,03226,511Mar 07 04:06 PM
Hoerter Steven L.Chief Commercial OfficerMar 04Option Exercise39.765,000198,80015,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 04Sale68.005,000340,00010,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 01Option Exercise39.765,000198,80015,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 01Sale66.015,000330,05010,941Mar 05 04:04 PM
Biller ScottChief Scientific OfficerFeb 27Option Exercise15.109,000135,87535,511Mar 01 04:02 PM
Biller ScottChief Scientific OfficerFeb 27Sale65.009,000585,00026,511Mar 01 04:02 PM
Biller ScottChief Scientific OfficerDec 21Option Exercise2.3420,50047,91924,637Dec 26 04:39 PM
Biller ScottChief Scientific OfficerNov 05Option Exercise9.053,00027,15053,932Nov 07 04:09 PM
Biller ScottChief Scientific OfficerNov 05Sale69.693,000209,07150,932Nov 07 04:09 PM
Biller ScottChief Scientific OfficerOct 05Option Exercise9.053,00027,15053,932Oct 09 04:09 PM
Biller ScottChief Scientific OfficerOct 05Sale69.793,000209,37750,932Oct 09 04:09 PM
Alenson CarmanPrincipal Accounting OfficerSep 28Sale76.4515211,6200Feb 20 04:01 PM
MARAGANORE JOHNDirectorSep 12Sale71.7414,1621,015,98222,047Sep 13 04:01 PM
MARAGANORE JOHNDirectorSep 11Sale72.7513,555986,12936,209Sep 13 04:01 PM
Schenkein David PChief Executive OfficerSep 10Option Exercise31.648,730276,21783,849Sep 12 04:12 PM
Biller ScottChief Scientific OfficerSep 05Option Exercise9.053,00027,15060,196Sep 07 04:12 PM
Alenson CarmanPrincipal Accounting OfficerSep 05Option Exercise52.2931216,314464Sep 07 04:18 PM
Schenkein David PChief Executive OfficerSep 05Option Exercise3.3275,119249,02875,119Sep 07 04:22 PM
Alenson CarmanPrincipal Accounting OfficerSep 05Sale83.0031225,896152Sep 07 04:18 PM
Biller ScottChief Scientific OfficerSep 05Sale83.073,000249,21557,196Sep 07 04:12 PM
Bowden ChristopherChief Medical OfficerAug 30Option Exercise35.161,70059,7722,624Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 30Sale80.031,700136,051924Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 29Option Exercise35.1630010,5481,224Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 29Sale80.0030024,000924Aug 31 04:02 PM
Hoerter Steven L.Chief Commercial OfficerAug 24Option Exercise39.762,05081,5082,050Aug 28 04:06 PM
Hoerter Steven L.Chief Commercial OfficerAug 24Sale74.922,050153,5860Aug 28 04:06 PM
Biller ScottChief Scientific OfficerAug 06Option Exercise9.053,00027,15060,196Aug 08 04:14 PM
Biller ScottChief Scientific OfficerAug 06Sale80.113,000240,33357,196Aug 08 04:14 PM
Hoerter Steven L.Chief Commercial OfficerJul 25Option Exercise39.762,05081,5082,050Jul 27 04:01 PM
Hoerter Steven L.Chief Commercial OfficerJul 25Sale84.582,050173,3890Jul 27 04:01 PM
Bowden ChristopherChief Medical OfficerJul 10Option Exercise35.162,00070,3202,924Jul 12 04:14 PM
Bowden ChristopherChief Medical OfficerJul 10Sale86.762,000173,512924Jul 12 04:14 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Option Exercise52.2927214,223272Jul 11 04:23 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Sale84.9427223,1040Jul 11 04:23 PM
Biller ScottChief Scientific OfficerJul 05Option Exercise9.053,00027,15060,196Jul 09 04:08 PM
Biller ScottChief Scientific OfficerJul 05Sale83.503,000250,50357,196Jul 09 04:08 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Option Exercise39.762,05081,5082,050Jun 26 04:02 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Sale97.582,050200,0390Jun 26 04:02 PM
Foster-Cheek Kaye IDirectorJun 14Option Exercise50.739,000456,57011,200Jun 18 04:05 PM
Foster-Cheek Kaye IDirectorJun 14Sale93.559,000841,9262,200Jun 18 04:05 PM
Bowden ChristopherChief Medical OfficerJun 12Option Exercise35.162,00070,3202,881Jun 14 04:23 PM
Bowden ChristopherChief Medical OfficerJun 12Sale92.892,000185,786881Jun 14 04:23 PM
Biller ScottChief Scientific OfficerJun 05Option Exercise9.053,00027,15060,196Jun 07 04:02 PM
Biller ScottChief Scientific OfficerJun 05Sale93.373,000280,10157,196Jun 07 04:02 PM
Schenkein David PChief Executive OfficerJun 01Option Exercise0.4813,0006,28013,000Jun 05 04:10 PM
Schenkein David PChief Executive OfficerJun 01Sale95.3513,0001,239,6080Jun 05 04:10 PM
Schenkein David PChief Executive OfficerMay 30Option Exercise0.3945,62617,67545,626Jun 01 04:08 PM
Schenkein David PChief Executive OfficerMay 30Sale90.0745,6264,109,5340Jun 01 04:08 PM
Biller ScottChief Scientific OfficerMay 23